


<OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
         xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
    <responseDate>2025-09-09T14:05:49Z</responseDate>
    <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:12405462" metadataPrefix="pmc">https://pmc.ncbi.nlm.nih.gov/api/oai/v1/mh/</request>
    
    <GetRecord>
        <record>
    <header>
    <identifier>oai:pubmedcentral.nih.gov:12405462</identifier>
    <datestamp>2025-09-04</datestamp>
    
        
        <setSpec>commsmed</setSpec>
        
    
        
        <setSpec>pmc-open</setSpec>
        
    
</header>
    <metadata>
        
        <article xmlns="https://jats.nlm.nih.gov/ns/archiving/1.4/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.4/ https://jats.nlm.nih.gov/archiving/1.4/xsd/JATS-archivearticle1-4.xsd" article-type="research-article" xml:lang="en" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Commun Med (Lond)</journal-id><journal-id journal-id-type="iso-abbrev">Commun Med (Lond)</journal-id><journal-id journal-id-type="pmc-domain-id">4189</journal-id><journal-id journal-id-type="pmc-domain">commsmed</journal-id><journal-title-group><journal-title>Communications Medicine</journal-title></journal-title-group><issn pub-type="epub">2730-664X</issn><publisher><publisher-name>Nature Publishing Group</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12405462</article-id><article-id pub-id-type="pmcid-ver">PMC12405462.1</article-id><article-id pub-id-type="pmcaid">12405462</article-id><article-id pub-id-type="pmcaiid">12405462</article-id><article-id pub-id-type="pmid">40897815</article-id><article-id pub-id-type="doi">10.1038/s43856-025-01108-x</article-id><article-id pub-id-type="publisher-id">1108</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Gene augmentation therapy restores vision and preserves photoreceptors in a mouse model of <italic toggle="yes">CNGA1</italic>-retinitis pigmentosa</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes" equal-contrib="yes"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0003-0232-5100</contrib-id><name name-style="western"><surname>Wu</surname><given-names initials="Y">Yidong</given-names></name><address><email>wuyidong@sjtu.edu.cn</email></address><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff3">3</xref><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author" equal-contrib="yes"><name name-style="western"><surname>Zhao</surname><given-names initials="T">Tianyuan</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author" equal-contrib="yes"><name name-style="western"><surname>Wang</surname><given-names initials="Y">Yazhi</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff3">3</xref><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author" equal-contrib="yes"><name name-style="western"><surname>Zhang</surname><given-names initials="T">Ting</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff3">3</xref><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author" equal-contrib="yes"><name name-style="western"><surname>Hang</surname><given-names initials="C">Chenyue</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Wang</surname><given-names initials="Y">Yafang</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Liu</surname><given-names initials="Y">Yang</given-names></name><xref ref-type="aff" rid="Aff5">5</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Chen</surname><given-names initials="Z">Zhixuan</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Chen</surname><given-names initials="J">Jieqiong</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff3">3</xref><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0002-2544-1254</contrib-id><name name-style="western"><surname>Li</surname><given-names initials="T">Tong</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff3">3</xref><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Sun</surname><given-names initials="J">Junran</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff3">3</xref><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0001-9341-5587</contrib-id><name name-style="western"><surname>Jia</surname><given-names initials="H">Huixun</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff3">3</xref><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Zhang</surname><given-names initials="L">Lei</given-names></name><xref ref-type="aff" rid="Aff5">5</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Wang</surname><given-names initials="F">Fenghua</given-names></name><xref ref-type="aff" rid="Aff4">4</xref><xref ref-type="aff" rid="Aff5">5</xref></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0003-4583-8686</contrib-id><name name-style="western"><surname>Wan</surname><given-names initials="X">Xiaoling</given-names></name><address><email>shaolin.72@163.com</email></address><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff3">3</xref><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0001-5015-0945</contrib-id><name name-style="western"><surname>Sun</surname><given-names initials="X">Xiaodong</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff3">3</xref><xref ref-type="aff" rid="Aff4">4</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/0220qvk04</institution-id><institution-id institution-id-type="GRID">grid.16821.3c</institution-id><institution-id institution-id-type="ISNI">0000 0004 0368 8293</institution-id><institution>Department of Ophthalmology, Shanghai General Hospital, </institution><institution>Shanghai Jiao Tong University School of Medicine, </institution></institution-wrap>Shanghai, China </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/04a46mh28</institution-id><institution-id institution-id-type="GRID">grid.412478.c</institution-id><institution-id institution-id-type="ISNI">0000 0004 1760 4628</institution-id><institution>National Clinical Research Center for Eye Diseases, </institution></institution-wrap>Shanghai, China </aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/04a46mh28</institution-id><institution-id institution-id-type="GRID">grid.412478.c</institution-id><institution-id institution-id-type="ISNI">0000 0004 1760 4628</institution-id><institution>Shanghai Key Laboratory of Ocular Fundus Diseases, </institution></institution-wrap>Shanghai, China </aff><aff id="Aff4"><label>4</label>Shanghai Engineering Center for Visual Science and Photomedicine, Shanghai, China </aff><aff id="Aff5"><label>5</label>Innostellar Biotherapeutics Co.Ltd, Shanghai, China </aff></contrib-group><pub-date pub-type="epub"><day>2</day><month>9</month><year>2025</year></pub-date><pub-date pub-type="collection"><year>2025</year></pub-date><volume>5</volume><issue-id pub-id-type="pmc-issue-id">478325</issue-id><elocation-id>384</elocation-id><history><date date-type="received"><day>12</day><month>7</month><year>2024</year></date><date date-type="accepted"><day>21</day><month>8</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>02</day><month>09</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>04</day><month>09</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-09-04 00:25:59.930"><day>04</day><month>09</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>&#169; The Author(s) 2025</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbyncndlicense">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref><license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article&#8217;s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article&#8217;s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">http://creativecommons.org/licenses/by-nc-nd/4.0/</ext-link>.</license-p></license></permissions><self-uri content-type="pmc-pdf" xlink:href="43856_2025_Article_1108.pdf"/><abstract id="Abs1"><sec><title>Background</title><p id="Par1">Retinitis pigmentosa (RP) is a leading cause of blindness affecting 2 million people worldwide. Mutations in cyclic nucleotide-gated channel alpha 1 (<italic toggle="yes">CNGA1</italic>) account for 2&#8211;8% of autosomal recessive RP with no available treatment. Here we further evaluate our previously developed <italic toggle="yes">Cnga1</italic><sup><italic toggle="yes">-/-</italic></sup> mouse model. We aim to present detailed phenotype data and assess the therapeutic efficacy of gene augmentation in this model.</p></sec><sec><title>Methods</title><p id="Par2">The retinal function and structure of <italic toggle="yes">Cnga1</italic><sup>-/-</sup> mice were accessed from postnatal month 1 to 6. AAV8-<italic toggle="yes">hRHO</italic>-<italic toggle="yes">mCnga1</italic> was constructed and delivered into the subretinal space of 2-week-old <italic toggle="yes">Cnga1</italic><sup>-/-</sup> mice. Retinal function, photoreceptor survival, and vision-guided behavior were evaluated following treatment.</p></sec><sec><title>Results</title><p id="Par3">Here we show that <italic toggle="yes">Cnga1</italic><sup>-/-</sup> mice have a similar phenotype to human patients, characterized by an early loss of rod-mediated retinal function and progressive photoreceptor degeneration, which is nearly complete by 6 months of age. Gene augmentation therapy results in robust expression of correctly localized CNGA1 protein, sustained rescue of retinal function and long-term preservation of photoreceptors for at least 9 months. Treated mice also show improved performance in a vision-guided behavior test. RNA-seq reveals upregulation of genes associated with phototransduction.</p></sec><sec><title>Conclusions</title><p id="Par4">To the best of our knowledge, this work demonstrates for the first time that a gene augmentation approach can restore vision and preserves photoreceptors in an animal model of <italic toggle="yes">CNGA1</italic>-RP. These findings pave the way for future development of gene augmentation therapy for patients with <italic toggle="yes">CNGA1</italic>-RP.</p></sec></abstract><abstract id="Abs2" abstract-type="plain-language-summary"><title>Plain language summary</title><p id="Par5">Retinitis pigmentosa (RP) is the most common inherited eye disease. It causes progressive vision loss and eventual blindness. Changes in a part of a person&#8217;s DNA called the <italic toggle="yes">CNGA1</italic> gene are a known cause of RP, but no treatments are currently available. In this study, we used a mouse model lacking the <italic toggle="yes">Cnga1</italic> gene to investigate disease features and determine whether adding the gene back into the mice, a treatment called gene therapy, could be a potential treatment. Healthy copies of the <italic toggle="yes">Cnga1</italic> gene were delivered into the eye. The treatment restored eye function and improved vision-guided behavior in treated mice. Our findings suggest that gene therapy is a promising treatment approach for people with RP caused by changes in the <italic toggle="yes">CNGA1</italic> gene.</p></abstract><abstract id="Abs3" abstract-type="web-summary"><p id="Par6">Wu, Zhao, Wang, Zhang, Hang et al. describe a mouse model of CNGA1-retinitis pigmentosa (RP) and the effect of AAV-mediated gene augmentation. The model replicates key features of human patients, and it demonstrates that AAV-mediated gene augmentation restores vision and preserves photoreceptors.</p></abstract><kwd-group kwd-group-type="npg-subject"><title>Subject terms</title><kwd>Retinal diseases</kwd><kwd>Gene therapy</kwd></kwd-group><funding-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">https://doi.org/10.13039/100012543</institution-id><institution>Shanghai Science and Technology Development Foundation (Shanghai Science and Technology Development Fund)</institution></institution-wrap></funding-source><award-id>24YF2734000</award-id><principal-award-recipient><name name-style="western"><surname>Wu</surname><given-names>Yidong</given-names></name></principal-award-recipient></award-group></funding-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#169; Springer Nature Limited 2025</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1" sec-type="introduction"><title>Introduction</title><p id="Par7">In the plasma membrane of the photoreceptor outer segments, cyclic nucleotide-gated (CNG) channels serve as the final target of phototransduction, converting light-induced changes in the second messenger cGMP into electrical signals<sup><xref ref-type="bibr" rid="CR1">1</xref>&#8211;<xref ref-type="bibr" rid="CR3">3</xref></sup>. Mutations in <italic toggle="yes">CNGA1</italic>, which encodes the alpha subunit of the rod photoreceptor CNG channel, are associated with autosomal recessive retinitis pigmentosa (RP)<sup><xref ref-type="bibr" rid="CR4">4</xref></sup>.</p><p id="Par8">RP is the most common inherited retinal disease, characterized by progressive rod-cone photoreceptor degeneration, affecting approximately 1 in 4000 people worldwide<sup><xref ref-type="bibr" rid="CR5">5</xref></sup>. To date, 89 genes have been identified to be associated with non-syndromic RP (RetNet, accessed on May 20, 2025). <italic toggle="yes">CNGA1</italic>-RP accounts for 2&#8211;8% cases of autosomal recessive RP<sup><xref ref-type="bibr" rid="CR4">4</xref>&#8211;<xref ref-type="bibr" rid="CR10">10</xref></sup>, for which there is currently no treatment. Natural history report of <italic toggle="yes">CNGA1</italic>-RP is still unavailable. However, case reports<sup><xref ref-type="bibr" rid="CR9">9</xref>&#8211;<xref ref-type="bibr" rid="CR16">16</xref></sup>, as well as our ongoing observation (<ext-link ext-link-type="pmc:clinical-trial" xlink:href="NCT03691168">NCT03691168</ext-link>), suggest that patients with <italic toggle="yes">CNGA1</italic>-RP exhibit night blindness from early childhood. The rate of photoreceptor degeneration is moderate, and many patients were deemed legally blind by middle age<sup><xref ref-type="bibr" rid="CR9">9</xref>&#8211;<xref ref-type="bibr" rid="CR16">16</xref></sup>. This disconnection between early-onset clinical symptoms and the relatively slow progression of structural loss offers a potentially wide time window for therapeutic intervention.</p><p id="Par9">Gene augmentation therapy holds great promise in treating inherited retinal diseases, as highlighted by Luxturna, the first FDA-approved gene therapy for <italic toggle="yes">RPE65</italic>-related retinal degeneration<sup><xref ref-type="bibr" rid="CR17">17</xref></sup>. However, the lack of a suitable disease model poses an obstacle to the development of therapeutics for <italic toggle="yes">CNGA1</italic>-RP<sup><xref ref-type="bibr" rid="CR18">18</xref>,<xref ref-type="bibr" rid="CR19">19</xref></sup>. Recently, we generated the first <italic toggle="yes">Cnga1</italic> knockout (<italic toggle="yes">Cnga1</italic><sup><italic toggle="yes">-/-</italic></sup>) mouse by introducing a 65&#8201;bp frame-shift deletion in exon 2<sup><xref ref-type="bibr" rid="CR20">20</xref></sup>. We found that in <italic toggle="yes">Cnga1</italic><sup>-/-</sup> mice, down-regulation of the PI3K-AKT-mTOR pathway triggered the rod photoreceptor death at postnatal day 9, which was exacerbated by the secondary activation of chaperone-mediated autophagy<sup><xref ref-type="bibr" rid="CR20">20</xref></sup>. The retinal phenotype was not described in detail in our previous publication (Liu et al.<sup><xref ref-type="bibr" rid="CR20">20</xref></sup>), e.g., the electroretinogram was recorded at a single flash intensity of 0.5&#8201;log&#8201;cd s m<sup>&#8722;2</sup>.</p><p id="Par10">In this study, we have two goals with the <italic toggle="yes">Cnga1</italic><sup>-/-</sup> mouse model: (i) to characterize the longitudinal changes of retinal phenotype in detail, and (ii) to evaluate the efficacy of gene augmentation therapy. We show that the mouse resembles a typical human <italic toggle="yes">CNGA1</italic>-RP phenotype, and introducing a normal copy of <italic toggle="yes">Cnga1</italic> into the rod photoreceptors result in sustained restoration of rod-mediated function and long-term preservation of retinal structure, as well as improvement in vision-guided behavior. This work provides preclinical proof-of-concept for AAV-mediated gene augmentation therapy for patients with <italic toggle="yes">CNGA1</italic>-RP.</p></sec><sec id="Sec2"><title>Methods</title><sec id="Sec3"><title>Ethics Statement</title><p id="Par11">The present study did not contain human data. The Institutional Review Board of Shanghai General Hospital has reviewed and approved the experiments described in this study. All animal procedures were conducted in adherence to the guidelines of the Association for Research in Vision and Ophthalmology Statement for the Use of Animals in Ophthalmic and Visual Research.</p></sec><sec id="Sec4"><title>Animals</title><p id="Par12">C57BL/6J mice and <italic toggle="yes">Cnga1</italic><sup><italic toggle="yes">-/-</italic></sup> mice were bred and housed at the animal facility of Shanghai General Hospital, where they were maintained under a 12&#8201;h/12&#8201;h light/dark cycle unless interruptions were required for experiments. The housing temperature ranged from 20&#8211;23&#8201;&#176;C, and the humidity fluctuated between 45%-55%. The mice were group-housed (3&#8211;5 per cage) in individually ventilated cages, with free access to water and a normal chow diet. The health status of mice was regularly monitored by institutional staff. The ratio of males to females was approximately 1:1 in all experiments. The age, strain, and number of mice used for each experiment are stated in the corresponding figure legends. Sample sizes for mouse experiments were based on prior experience of suitable n numbers and a minimum of n of 3 for each condition<sup><xref ref-type="bibr" rid="CR21">21</xref></sup>. Mice were randomly assigned to treatment and control groups using a computer-generated randomization sequence. At the end of the study, the mice were humanely euthanized by carbon dioxide exposure. Different cohorts of mice were used for OCT imaging and electroretinography experiments to avoid repeated anesthesia. The researchers were not blinded to group allocation as the subsequent experiments were carried by the same researchers from the beginning.</p></sec><sec id="Sec5"><title>In vivo OCT imaging</title><p id="Par13">OCT imaging was performed using Micron IV System (Phoenix Research Laboratories, Pleasanton, CA, USA) as previously described<sup><xref ref-type="bibr" rid="CR20">20</xref></sup>. After induction of anesthesia, pupils were dilated with 0.5% tropicamide and 0.5% phenylephrine hydrochloride (Mydrin-P, Santen), and ocular surfaces were kept hydrated with 0.3% hypromellose gel (GenTeal, Alcon). The mice were carefully positioned to ensure that the optic nerve head (ONH) was centered in the image. B-scan images crossing the ONH were captured for analysis. The thickness of the retinal ONL (photoreceptor nuclei) was quantified using Insight software (Phoenix Research Laboratories, Pleasanton, CA, USA). For the natural history study, the ONL thickness was determined from captured images at four positions, each &#8764;500&#8201;&#956;m away from the ONH in the superior, inferior, nasal, and temporal regions of the retina, and the values were averaged for analysis. For the gene augmentation study, considering that the AAV vectors delivered by subretinal injection reached only a fraction of the retina, we selected the temporal position &#8764;500&#8201;&#956;m from the ONH for analysis, based on the delivery route (please see below &#8216;Subretinal injection&#8217; section).</p></sec><sec id="Sec6"><title>Electroretinography</title><p id="Par14">Full-field ERGs were recorded using the Celeris Rodent Electrophysiology System (Diagnosys LLC, Lowell, MA, USA)<sup><xref ref-type="bibr" rid="CR21">21</xref></sup>. Mice were dark-adapted for at least 12&#8201;hours prior to testing. Under dim red light, animals were anesthetized with an intraperitoneal injection of pentobarbital sodium (50&#8201;mg/kg), and pupils were dilated using a mixture of 0.5% tropicamide and 0.5% phenylephrine hydrochloride (Mydrin-P, Santen). Corneal surfaces were protected and electrically coupled with 0.3% hypromellose gel (GenTeal, Alcon).</p><p id="Par15">Scotopic ERG responses were elicited using white light flashes at increasing intensities (&#8722;2.0, &#8722;1.5, &#8722;1.0, &#8722;0.5, 0, 0.5, and 1.0&#8201;log&#8201;cd s m<sup>&#8722;2</sup>). For photopic ERG testing, animals were first light-adapted for 10&#8201;minutes under a background light of 1.5&#8201;log&#8201;cd s m<sup>&#8722;2</sup>. Subsequent flashes of &#8722;1.0, 0, 1, and 2&#8201;log&#8201;cd s m<sup>&#8722;2</sup> were delivered under the same background illumination. Data were analyzed with the Espion software V6 (Diagnosys LLC, Lowell, MA, USA).</p></sec><sec id="Sec7"><title>AAV generation for in vivo delivery</title><p id="Par16">Murine <italic toggle="yes">Cnga1</italic>, driven by a human Rhodopsin promoter (primer forward 5&#8217;-AGC CCA GAT CTT CCC CAC CT-3&#8217; and reverse 5&#8217;-GAC TCT GGG TTC TGA CCC CC-3&#8217;), was inserted into the pAAV-MCS vector (Stratagene, CA, USA). The construct for AAV packaging was sequenced prior to packaging using Sanger sequencing. AAV vectors were packaged by co-transfecting a triple-plasmid system into HEK293T cells (ATCC), purified by a discontinuous gradient of iodixanol via ultracentrifugation, and titered by quantitative PCR (qPCR) using SYBR Green technology.</p></sec><sec id="Sec8"><title>Subretinal injection</title><p id="Par17">Subretinal injection was performed under a surgical microscope (Eder Medical Technology, Shanghai, CN) as previously described<sup><xref ref-type="bibr" rid="CR21">21</xref></sup>. Two-week-old <italic toggle="yes">Cnga1</italic><sup><italic toggle="yes">-/-</italic></sup> mice were anesthetized by intraperitoneal injection of pentobarbital sodium (50&#8201;mg/kg), and their pupils were dilated with 0.5% tropicamide and 0.5% phenylephrine hydrochloride (Mydrin-P, Santen). An incision was made through the sclera behind the iris at the nasal side using a 32-gauge needle. A NanoFil syringe with a 36-gauge blunt-end needle (World Precision Instruments, Sarasota, FL, USA) was then inserted through the incision and advanced to the subretinal space of the temporal side. One microliter of viral vector suspension (1&#8201;&#215;&#8201;10<sup>12</sup>&#8201;vg/ml) was slowly injected, leading to the formation of a visible bleb. Following injection, mice were placed on a heating pad for recovery, and the injected eyes were treated with 0.3% tobramycin and 0.1% dexamethasone (TobraDex, Alcon) for prevention of infection. The eyes with complications from the injection procedure, such as hemorrhage or damage to the lens, were excluded from the study and subsequent analysis.</p></sec><sec id="Sec9"><title>Immunohistochemistry</title><p id="Par18">Following enucleation, mouse eyes were immersed in 4% paraformaldehyde (PFA) in PBS for 10&#8201;min, followed by the removal of the cornea and lens under a dissecting microscope. Eyecups were then fixed in 4% PFA for an additional 60&#8201;min, washed with PBS three times for 5&#8201;min each, and were dehydrated sequentially with 10%, 20%, and 30% sucrose in PBS for 30&#8201;min each. After dehydration, eyecups were flash-frozen in O.C.T. (catalog 4583, Sakura) for cryosectioning at 12&#8201;&#956;m thickness (CM3050S, Leica). For immunostaining, the retinal sections were washed with PBS for 5&#8201;min and were blocked with 5% goat serum in 0.3% Triton X-100 in PBS. After blocking, retinal sections were incubated at 4&#8201;&#176;C overnight with mouse anti-CNGA1 antibody (1:200, catalog ab253296, Abcam), rabbit anti-cGMP antibody (1:200, catalog ab169753, Abcam), or rabbit anti-cone arrestin antibody (1:500, catalog AB15282, Millipore). Retinal sections were washed with PBS 3 times for 10&#8201;min each and incubated with secondary antibodies, including goat anti-mouse IgG antibody (1:1000, catalog A11005, Thermo Fisher) and goat anti-rabbit IgG antibody (1:1000, catalog A11008, Thermo Fisher). Nuclei were stained with DAPI (1:2000, catalog D1306, Thermo Fisher). The slides were then mounted with Fluoromount-G medium (catalog 0100-01, Southern Biotech) and imaged with the Leica SP8 Lightning System.</p></sec><sec id="Sec10"><title>Histology</title><p id="Par19">The eyes were fixed in 4% PFA for 24&#8201;h and embedded in paraffin, followed by sectioning at 5&#8201;&#956;m through the optic disk. Staining was performed with a commercial hematoxylin and eosin kit (catalog G1003, Servicebio). Slides were imaged using an Olympus BX53 microscope.</p></sec><sec id="Sec11"><title>RNA-Seq and real-time qPCR</title><p id="Par20">Total RNA of retinas was extracted using the TRIzol reagent (Invitrogen, CA, USA) according to the manufacturer&#8217;s protocol. The transcriptome sequencing was conducted by OE Biotech Co., Ltd. (Shanghai, China) using an Illumina Novaseq 6000 platform. Raw data were deposited in the Sequence Read Archive database (accession number PRJNA1214527). Gene Set Enrichment Analysis (GSEA) was performed using GSEA software. All reactions were performed on an ABI Prism 7900HT Sequence Detection System (Applied Biosystems) using SYBR green (RR420A, Takara, Japan). The associated primers were listed in Supplementary Table&#160;<xref rid="MOESM1" ref-type="media">1</xref>.</p></sec><sec id="Sec12"><title>Vision-guided behavior testing</title><p id="Par21">The Morris water maze test was modified to assess vision-dependent behavior as previously described<sup><xref ref-type="bibr" rid="CR21">21</xref>,<xref ref-type="bibr" rid="CR22">22</xref></sup>. In brief, mice were given a maximum of 60&#8201;seconds to locate a visible circular platform (0.01 m2, 0.5&#8201;cm above the water level) within a circular pool (1.44 m<sup>2</sup>, white plastic) filled with water at a temperature of 23&#8201;&#177;&#8201;2&#8201;&#176;C. The water was made opaque by the addition of nontoxic white pigment (titanium dioxide, JiangHuTaiBai). No intentional cues, apart from the platform, were provided. To evaluate rod-mediated vision, mice were dark-adapted for at least 12&#8201;h before testing, and the experiment was performed under very dim light (&#8804; 0.01 lux at the water level, measured with MAVOLUX 5032B, Gossen, GER).</p><p id="Par22">The experiment was performed on three consecutive days. Each mouse was tested two blocks of four trials per day. During each trial, the mouse was placed in the water from one of four equally spaced starting locations. The starting location was changed in a pseudo-random manner, whereas the platform was kept in a constant location. One trial ended if the mouse climbed onto the platform or if the mouse did not find the platform after 60&#8201;seconds. In the latter case, the mouse would be gently placed onto the platform. The mouse was left on the platform during the inter-trial interval for 20&#8201;seconds. After each block, the mouse was towel-dried and transferred to its home cage under warm air. The inter-block interval was approximately two hours. Each mouse completed 24 trials (6 blocks) in total during the three-day period. Behavior data were automatically recorded and analyzed with the EthoVision XT tracking system (Noldus, Wageningen, Netherlands). The main outcomes included the time required to reach the platform and the total path length. The latency of mice who did not find the platform within the time limit was recorded as the maximum (60&#8201;s) for data analysis.</p></sec><sec id="Sec13"><title>Statistics and reproducibility</title><p id="Par23">Statistical analysis was performed using GraphPad Prism (9.5.0) software. The statistical tests and the sample sizes used for each experiment are stated in the corresponding figure legends. The experiments were performed in at least three biologically independent animals, and similar results were observed.</p></sec><sec id="Sec14"><title>Reporting summary</title><p id="Par24">Further information on research design is available in the&#160;<xref rid="MOESM4" ref-type="media">Nature Portfolio Reporting Summary</xref> linked to this article.</p></sec></sec><sec id="Sec15" sec-type="results"><title>Results</title><sec id="Sec16"><title>Cnga1<sup>-/-</sup> mice show a progressive loss of photoreceptor cells</title><p id="Par25">We first monitored the photoreceptors over time, as they are the primarily affected cells of RP, and they are the target cells for <italic toggle="yes">Cnga1</italic> gene augmentation therapy. Using in vivo optical coherence tomography (OCT) imaging, we observed a progressive, almost linear thinning of the outer nuclear layer (ONL, representing photoreceptor nuclei) in <italic toggle="yes">Cnga1</italic><sup><italic toggle="yes">-/-</italic></sup> mice. The thickness of ONL reduced to 46% of the wild-type at the age of 3 months and became hardly discernible by the age of 6 months (Fig.&#160;<xref rid="Fig1" ref-type="fig">1A, B</xref>). An important sign detected by OCT was a &#8216;diffusely-hyperreflective&#8217; appearance and the gradual loss of the IS/OS band (representing the junction of photoreceptor inner and outer segments) from one month postnatal onward. This sign is frequently observed in patients with RP<sup><xref ref-type="bibr" rid="CR23">23</xref>&#8211;<xref ref-type="bibr" rid="CR26">26</xref></sup>, indicating an unhealthy status of the photoreceptor cells. Hematoxylin and eosin staining demonstrated that only 1&#8211;2 rows of ONL remained by 6 months of age (Supplementary Fig.&#160;<xref rid="MOESM1" ref-type="media">1</xref>). With the progression of rod photoreceptor degeneration, we found that cone morphology was also compromised in <italic toggle="yes">Cnga1</italic><sup><italic toggle="yes">-/-</italic></sup> mice (Fig.&#160;<xref rid="Fig1" ref-type="fig">1C</xref>). This is consistent with what was observed in human patients with RP<sup>5</sup>.<fig id="Fig1" position="float" orientation="portrait"><label>Fig. 1</label><caption><title><italic toggle="yes">Cnga1</italic><sup><italic toggle="yes">-/-</italic></sup> mice show a progressive loss of photoreceptor cells.</title><p><bold>A</bold> Representative OCT images of wild-type and <italic toggle="yes">Cnga1</italic><sup><italic toggle="yes">-/-</italic></sup> mice. Asterisks mark the photoreceptor nuclei layer. Scale bars, 100&#8201;&#956;m. <bold>B</bold> Age-related thinning of the photoreceptor nuclei layer of <italic toggle="yes">Cnga1</italic><sup><italic toggle="yes">-/-</italic></sup> mice compared with wild-type mice, as measured by OCT images. Mean&#8201;&#177;&#8201;SD. <italic toggle="yes">n</italic>&#8201;=&#8201;6 eyes for both group at each time point. <bold>C</bold> Representative confocal images of immunohistochemistry with CNGA1 (red) and cone arrestin (CAR, a cone marker, green) show morphologically affected but still-persisting cones after advanced thinning of the photoreceptor nuclei layer in <italic toggle="yes">Cnga1</italic><sup><italic toggle="yes">-/-</italic></sup> mice. Scale bar, 10&#8201;&#956;m.</p></caption><graphic id="d33e652" position="float" orientation="portrait" xlink:href="43856_2025_1108_Fig1_HTML.jpg"/></fig></p></sec><sec id="Sec17"><title>Cnga1<sup>-/-</sup> mice show a lack of rod-driven response to light</title><p id="Par26">We next investigated the effect of CNGA1 deficiency on retinal function using full-field ERGs. This technique assesses the electrical response of the retina to a flash stimulus, with its two main components being the a-wave, a negative potential reflecting photoreceptor activity, and the subsequent positive b-wave, reflecting the activity of downstream retinal interneurons<sup><xref ref-type="bibr" rid="CR27">27</xref>,<xref ref-type="bibr" rid="CR28">28</xref></sup>.</p><p id="Par27">We recorded scotopic ERGs (rod-dominated) in dark-adapted mice using a series of flash stimuli (Fig.&#160;<xref rid="Fig2" ref-type="fig">2</xref>). Three standard stimulus intensities were incorporated as per the recommendation of the International Society for Clinical Electrophysiology of Vision (ISCEV)<sup><xref ref-type="bibr" rid="CR29">29</xref></sup>: &#8722;2 log cd s m<sup>&#8722;2</sup> for a rod-specific response, and 0.5 and 1&#8201;log&#8201;cd s m<sup>&#8722;2</sup> as a &#8216;standard&#8217; and a &#8216;strong&#8217; flash, respectively, both having mixed rod-cone contribution. For wild-type mice at the age of one month, the b-wave was clearly visible starting at the intensity of &#8722;2 log cd s m<sup>&#8722;2</sup> (Fig.&#160;<xref rid="Fig2" ref-type="fig">2A</xref>). With increasing stimulus intensities, the a-wave emerged and the amplitudes of both a- and b-waves increased steadily (Fig.&#160;<xref rid="Fig2" ref-type="fig">2A</xref>). In contrast, the <italic toggle="yes">Cnga1</italic><sup>-/-</sup> mice showed no response to the rod-specific flash at &#8722;2 log cd s m<sup>&#8722;2</sup> (Fig.&#160;<xref rid="Fig2" ref-type="fig">2A</xref>). With higher light intensities, the ERG waveforms lacked a distinct a-wave and typical oscillations on the peak of b-wave (Fig.&#160;<xref rid="Fig2" ref-type="fig">2A</xref>), both indicators of rod system activity<sup><xref ref-type="bibr" rid="CR27">27</xref>,<xref ref-type="bibr" rid="CR28">28</xref></sup>. These observations suggest that the rod system is not functional in the <italic toggle="yes">Cnga1</italic><sup>-/-</sup> mouse. Indeed, the scotopic ERG waveforms of <italic toggle="yes">Cnga1</italic><sup>-/-</sup> mice are similar to those found in the mouse models of pure cone function, such as the <italic toggle="yes">Rho</italic><sup>-/-</sup> mouse<sup><xref ref-type="bibr" rid="CR30">30</xref></sup>. The b-wave amplitudes of <italic toggle="yes">Cnga1</italic><sup>-/-</sup> mice significantly declined with age (Fig.&#160;<xref rid="Fig2" ref-type="fig">2B, C</xref>), which is in keeping with the photoreceptor degeneration (Fig.&#160;<xref rid="Fig1" ref-type="fig">1C, D</xref>). By 6 months of age, no discernible ERG signals were left in <italic toggle="yes">Cnga1</italic><sup>-/-</sup> mice, whereas the wild-type mice showed only an age-related decrease in amplitudes<sup><xref ref-type="bibr" rid="CR31">31</xref></sup> (Fig.&#160;<xref rid="Fig2" ref-type="fig">2B, C</xref>).<fig id="Fig2" position="float" orientation="portrait"><label>Fig. 2</label><caption><title><italic toggle="yes">Cnga1</italic><sup><italic toggle="yes">-/-</italic></sup> mice show a loss of rod-mediated retinal function.</title><p><bold>A</bold> Representative scotopic (dark-adapted) ERG waveforms in response to a series of flashes. Stimulus intensities are indicated in the left panel. <bold>B</bold> Quantification of b-wave amplitudes of <italic toggle="yes">Cnga1</italic><sup>-/-</sup> mice compared to wild-type mice at 1 month of age (left), 3 months of age (middle) and 6 months of age (right). Mean&#8201;&#177;&#8201;SEM. <bold>C</bold> Changes in b-wave amplitudes with age at ISCEV standard flashes of &#8722;2 log cd s m<sup>&#8722;2</sup> (left), 0.5&#8201;log&#8201;cd s m<sup>&#8722;2</sup> (middle), and 1&#8201;log&#8201;cd s m<sup>&#8722;2</sup> (right). Mean&#8201;&#177;&#8201;SEM. For the wild-type group, <italic toggle="yes">n</italic>&#8201;=&#8201;10 eyes at each time point. For the <italic toggle="yes">Cnga1</italic><sup><italic toggle="yes">-/-</italic></sup> group, <italic toggle="yes">n</italic>&#8201;=&#8201;12 eyes at month 1 and 3; <italic toggle="yes">n</italic>&#8201;=&#8201;10 eyes at month 2, 4, 5; <italic toggle="yes">n</italic>&#8201;=&#8201;8 eyes at month 6.</p></caption><graphic id="d33e800" position="float" orientation="portrait" xlink:href="43856_2025_1108_Fig2_HTML.jpg"/></fig></p><p id="Par28">To directly compare the cone function between the wild-type and <italic toggle="yes">Cnga1</italic><sup>-/-</sup> mouse, we further performed photopic (light-adapted) ERGs (Fig.&#160;<xref rid="Fig3" ref-type="fig">3</xref>). For wild-type mice, b-waves were evident when the stimulus intensity rose to 1&#8201;log&#8201;cd s m<sup>&#8722;2</sup>, and a slight a-wave was visible at the highest stimulus intensity. No marked difference was found in the shape of the waveforms between wild-type mice and <italic toggle="yes">Cnga1</italic><sup>-/-</sup> mice (Fig.&#160;<xref rid="Fig3" ref-type="fig">3A</xref>). However, the b-wave amplitudes in <italic toggle="yes">Cnga1</italic><sup>-/-</sup> mice were significantly larger than those in wild-type mice during the first two months postnatally (Fig.&#160;<xref rid="Fig3" ref-type="fig">3B</xref>, C). Likewise, this &#8216;supernormal&#8217; phenomenon has been reported in the <italic toggle="yes">Rho</italic><sup>-/-</sup> mouse<sup><xref ref-type="bibr" rid="CR30">30</xref></sup>. The underlying mechanism might be attributed to cone degeneration<sup><xref ref-type="bibr" rid="CR32">32</xref>&#8211;<xref ref-type="bibr" rid="CR34">34</xref></sup> and warrants further investigation.<fig id="Fig3" position="float" orientation="portrait"><label>Fig. 3</label><caption><title><italic toggle="yes">Cnga1</italic><sup><italic toggle="yes">-/-</italic></sup> mice show a &#8216;supernormal&#8217; phase of cone-mediated function followed by a subsequent decline with age.</title><p><bold>A</bold> Representative photopic (light-adapted) ERG waveforms in response to a series of flashes. Stimulus intensities are indicated in the left panel. <bold>B</bold> Quantification of b-wave amplitudes of <italic toggle="yes">Cnga1</italic><sup>-/-</sup> mice compared to wild-type mice at 1 month (left), 3 months (middle) and 6 months (right) of age. Mean&#8201;&#177;&#8201;SEM. <bold>C</bold> Changes in b-wave amplitudes with age at stimulus intensities of 1.0&#8201;log&#8201;cd s m<sup>&#8722;2</sup> (left) and 2.0&#8201;log&#8201;cd s m<sup>&#8722;2</sup> (right). Mean&#8201;&#177;&#8201;SEM. For the wild-type group, <italic toggle="yes">n</italic>&#8201;=&#8201;10 eyes at each time point. For the <italic toggle="yes">Cnga1</italic><sup><italic toggle="yes">-/-</italic></sup> group, <italic toggle="yes">n</italic>&#8201;=&#8201;12 eyes at month 1 and 3; <italic toggle="yes">n</italic>&#8201;=&#8201;10 eyes at month 2, 4, 5; <italic toggle="yes">n</italic>&#8201;=&#8201;8 eyes at month 6.</p></caption><graphic id="d33e893" position="float" orientation="portrait" xlink:href="43856_2025_1108_Fig3_HTML.jpg"/></fig></p><p id="Par29">In summary, the ERG analysis indicates a lack of rod-driven response in the <italic toggle="yes">Cnga1</italic><sup>-/-</sup> mouse, and reveals a progressive loss of cone-mediated function with an initial &#8216;supernormal&#8217; phase.</p></sec><sec id="Sec18"><title>Gene augmentation therapy restores functional rod CNG channels, reverses cGMP accumulation, and rescues rod function</title><p id="Par30">In retina, CNGA1 is selectively expressed in rod photoreceptors, forming the CNG channel with CNGB1 in a 3:1 stoichiometry<sup><xref ref-type="bibr" rid="CR1">1</xref></sup>. The CNGA1 subunits confer the principal channel properties, whereas the CNGB1 subunit mainly contributes to outer segments localization<sup><xref ref-type="bibr" rid="CR1">1</xref>,<xref ref-type="bibr" rid="CR35">35</xref></sup>. Given the above information, we employed an adeno-associated virus (AAV) vector serotype 8 (for photoreceptor tropism<sup><xref ref-type="bibr" rid="CR36">36</xref></sup>) to deliver murine <italic toggle="yes">Cnga1</italic> under the control of a human rhodopsin promoter (for rod-specific expression; AAV8-<italic toggle="yes">hRHO</italic>-<italic toggle="yes">mCnga1</italic>). We first conducted a pilot dose-escalation study comparing three doses of AAV8-<italic toggle="yes">hRHO-mCnga1</italic> (10<sup>8</sup>, 10<sup>9</sup>, and 10<sup>10</sup> vg/eye). Efficacy was evaluated using a &#8722;2 log cd s m<sup>&#8722;2</sup> flash stimulus, a rod-specific intensity recommended by ISCEV<sup><xref ref-type="bibr" rid="CR29">29</xref></sup>, which elicits a negligible response in <italic toggle="yes">Cnga1</italic><sup>&#8315;/&#8315;</sup> mice (Fig.&#160;<xref rid="Fig2" ref-type="fig">2</xref>). The 10<sup>9</sup> vg/eye dose produced the most robust functional rescue and was therefore selected for subsequent experiments (Supplementary Fig.&#160;<xref rid="MOESM1" ref-type="media">2</xref>). Approximately 10<sup>9</sup> genome copies of AAV8-<italic toggle="yes">hRHO</italic>-<italic toggle="yes">mCnga1</italic> were injected into the subretinal space of 2-week-old <italic toggle="yes">Cnga1</italic><sup>-/-</sup> mice (Fig.&#160;<xref rid="Fig4" ref-type="fig">4A</xref>). Immunohistochemical assay of retinas 2.5 months post-injection showed that the introduced <italic toggle="yes">Cnga1</italic> was successfully expressed and accurately localized to the rod outer segments (Fig.&#160;<xref rid="Fig4" ref-type="fig">4B</xref>), suggesting the formation of the rod CNG channel complex. The correct localization of CNGA1 was further confirmed by co-staining with rhodopsin (Supplementary Fig.&#160;<xref rid="MOESM1" ref-type="media">3</xref>). A major feature of impaired CNG channel function is the abnormal concentration of cGMP<sup><xref ref-type="bibr" rid="CR1">1</xref></sup>, which triggers photoreceptor death<sup><xref ref-type="bibr" rid="CR2">2</xref>,<xref ref-type="bibr" rid="CR37">37</xref></sup>. We found that this toxic accumulation was reversed in the treated retina, whereas cGMP levels remained high in untreated eyes (Fig.&#160;<xref rid="Fig4" ref-type="fig">4B</xref>).<fig id="Fig4" position="float" orientation="portrait"><label>Fig. 4</label><caption><title>Formation of functional rod CNG channel in <italic toggle="yes">Cnga1</italic><sup><italic toggle="yes">-/-</italic></sup> mice after gene augmentation therapy.</title><p><bold>A</bold> Map of gene expression cassette for subretinal delivery and the experimental timeline. The data shown in (B-E) are from mice at 3 months of age. <bold>B</bold> Representative confocal images showing the expression of correctly localized CNGA1 protein (red) and lack of cGMP accumulation in treated retina. Scale bar, 10&#8201;&#956;m. <bold>C</bold> Representative scotopic (dark-adapted) ERG waveforms in response to a series of flashes from wild-type mouse (left), untreated <italic toggle="yes">Cnga1</italic><sup><italic toggle="yes">-/-</italic></sup> mouse (middle) and treated <italic toggle="yes">Cnga1</italic><sup><italic toggle="yes">-/-</italic></sup> mouse (right). <bold>D</bold> Quantification of a-wave amplitudes of untreated and treated <italic toggle="yes">Cnga1</italic><sup>-/-</sup> mice. Mean&#8201;&#177;&#8201;SEM. **<italic toggle="yes">P</italic>&#8201;&lt;&#8201;0.01, ***<italic toggle="yes">P</italic>&#8201;&lt;&#8201;0.001; two-way ANOVA with &#352;&#237;d&#225;k&#8217;s multiple comparisons. <italic toggle="yes">P</italic> values are 0.0001 at &#8722;0.5, 0.0011 at 0, and &lt;0.0001 at higher light intensities. <bold>E</bold> Quantification of b-wave amplitudes of untreated and treated <italic toggle="yes">Cnga1</italic><sup>-/-</sup> mice. Mean&#8201;&#177;&#8201;SEM. ***<italic toggle="yes">P</italic>&#8201;&lt;&#8201;0.001; two-way ANOVA with &#352;&#237;d&#225;k&#8217;s multiple comparisons. <italic toggle="yes">P</italic> values are 0.0006 at &#8722;2, 0.0003 at &#8722;1.5, 0.0001 at &#8722;1, and &lt;0.0001 at higher light intensities. Treated <italic toggle="yes">Cnga1</italic><sup><italic toggle="yes">-/-</italic></sup>, <italic toggle="yes">n</italic>&#8201;=&#8201;10 eyes; untreated <italic toggle="yes">Cnga1</italic><sup><italic toggle="yes">-/-</italic></sup>, <italic toggle="yes">n</italic>&#8201;=&#8201;10 eyes.</p></caption><graphic id="d33e1083" position="float" orientation="portrait" xlink:href="43856_2025_1108_Fig4_HTML.jpg"/></fig></p><p id="Par31">Further evidence that CNGA1, together with CNGB1, had formed functional CNG channels was provided by scotopic ERG analysis. Figure&#160;<xref rid="Fig4" ref-type="fig">4C</xref> shows the representative ERG waveforms of wild-type (left), untreated <italic toggle="yes">Cnga1</italic><sup>-/-</sup> (middle), and treated <italic toggle="yes">Cnga1</italic><sup>-/-</sup> (right) eyes 2.5 months post-treatment. At the ISCEV rod-specific flash of &#8722;2 log cd s m<sup>&#8722;2</sup>, the treated <italic toggle="yes">Cnga1</italic><sup>-/-</sup> eye exhibited a clear positive b-wave, while the untreated <italic toggle="yes">Cnga1</italic><sup>-/-</sup> eye did not show a response (Fig.&#160;<xref rid="Fig4" ref-type="fig">4C</xref>). Furthermore, a slight recovery of a-wave was observed starting from &#8722;1 log cd s m<sup>&#8722;2</sup> upward (Fig.&#160;<xref rid="Fig4" ref-type="fig">4C</xref>). The amplitudes of both a- and b-waves in treated <italic toggle="yes">Cnga1</italic><sup>-/-</sup> eyes showed a clear and statistically significant improvement across all tested stimulus intensity (Fig.&#160;<xref rid="Fig4" ref-type="fig">4D, E</xref>). Together, these scotopic ERG findings validated the functional recovery of the rod CNG channel following gene augmentation therapy with AAV8-<italic toggle="yes">hRHO-mCnga1</italic>.</p></sec><sec id="Sec19"><title>Gene augmentation therapy prolongs photoreceptor survival in Cnga1<sup>-/-</sup> mice</title><p id="Par32">Patients with <italic toggle="yes">CNGA1</italic>-RP are characterized by progressive photoreceptor degeneration, which is also observed in the <italic toggle="yes">Cnga1</italic><sup><italic toggle="yes">-/-</italic></sup> mouse model (Fig.&#160;<xref rid="Fig1" ref-type="fig">1</xref> and Supplementary Fig.&#160;<xref rid="MOESM1" ref-type="media">1</xref>). We therefore followed treated <italic toggle="yes">Cnga1</italic><sup><italic toggle="yes">-/-</italic></sup> mice to evaluate whether the gene augmentation therapy could halt or delay the photoreceptor death, thereby enabling long-term functional rescue. In vivo OCT images crossing the optic nerve head revealed that subretinal delivery of AAV8-<italic toggle="yes">hRHO</italic>-<italic toggle="yes">mCnga1</italic> led to a significant preservation of photoreceptor nuclei in the ONL within the treated region compared with the opposite untreated area of the same eye or in the eyes of untreated <italic toggle="yes">Cnga1</italic><sup><italic toggle="yes">-/-</italic></sup> mice (Fig.&#160;<xref rid="Fig5" ref-type="fig">5A</xref>). This structural rescue detected by OCT was evident at the age of 3 months and persisted up to the end of the experiment at the age of 9 months (Fig.&#160;<xref rid="Fig5" ref-type="fig">5A, B</xref>).<fig id="Fig5" position="float" orientation="portrait"><label>Fig. 5</label><caption><title>Long-term preservation of photoreceptors in <italic toggle="yes">Cnga1</italic><sup><italic toggle="yes">-/-</italic></sup> mice following gene augmentation therapy.</title><p><bold>A</bold> Representative OCT images from treated <italic toggle="yes">Cnga1</italic><sup><italic toggle="yes">-/-</italic></sup> mice at 3 months (top), 6 months (middle), and 9 months (bottom) of age showing clear preservation of photoreceptor layer thickness within the treated area. Asterisks mark the photoreceptor nuclei layer. ONH, optic nerve head. Scale bars, 100&#8201;&#956;m. <bold>B</bold> Quantification of the photoreceptor layer thickness in treated <italic toggle="yes">Cnga1</italic><sup><italic toggle="yes">-/-</italic></sup> retinae compared with untreated <italic toggle="yes">Cnga1</italic><sup><italic toggle="yes">-/-</italic></sup> and wild-type retinae, as measured by OCT images. Mean&#8201;&#177;&#8201;SEM. ***<italic toggle="yes">P</italic>&#8201;&lt;&#8201;0.001; two-way ANOVA with Tukey&#8217;s multiple comparisons. <italic toggle="yes">P</italic> value is &lt;0.0001. <italic toggle="yes">n</italic>&#8201;=&#8201;6 for each group at each time point. <bold>C</bold> Representative eye section from a 9-month-old treated <italic toggle="yes">Cnga1</italic><sup><italic toggle="yes">-/-</italic></sup> mouse. GCL, ganglion cell layer; INL, inner nuclear layer; ONL, outer nuclear layer. Scale bars, 200&#8201;&#956;m in the middle panel and 50&#8201;&#956;m in the magnified panels.</p></caption><graphic id="d33e1233" position="float" orientation="portrait" xlink:href="43856_2025_1108_Fig5_HTML.jpg"/></fig></p><p id="Par33">A representative hematoxylin and eosin staining of a 9-month-old treated retina is shown in Fig.&#160;<xref rid="Fig5" ref-type="fig">5C</xref>. It is, again, evident that the gene augmentation therapy resulted in robust protection of photoreceptors, confirming the OCT results. The ONL was 6-7 rows in the treated area, which in striking contrast to the untreated area in the same eye, where only a discontinuous row of ONL remained. Moreover, the inner and outer segments of photoreceptors were also preserved, as demonstrated in the magnified fragments (Fig.&#160;<xref rid="Fig5" ref-type="fig">5C</xref>). In <italic toggle="yes">Cnga1</italic><sup><italic toggle="yes">-/-</italic></sup> mice, rod degeneration leads to secondary cone degeneration (Fig.&#160;<xref rid="Fig1" ref-type="fig">1C</xref>). To evaluate treatment effects on cones, we immunolabeled retinal sections with anti-cone arrestin antibody. As expected, cone photoreceptors were preserved in treated region, whereas degeneration continued in untreated areas (Supplementary Fig.&#160;<xref rid="MOESM1" ref-type="media">4</xref>).</p><p id="Par34">We also evaluated the functional status of preserved photoreceptors at the age of 9 months (Fig.&#160;<xref rid="Fig6" ref-type="fig">6</xref>). Scotopic and photopic ERG recordings in the treated <italic toggle="yes">Cnga1</italic><sup><italic toggle="yes">-/-</italic></sup> mice revealed clear preservation of the light responses, indicating sustained functional rescue of both rod and cone photoreceptors (Fig.&#160;<xref rid="Fig6" ref-type="fig">6</xref>).<fig id="Fig6" position="float" orientation="portrait"><label>Fig. 6</label><caption><title>Long-term rescue of retinal function in <italic toggle="yes">Cnga1</italic><sup><italic toggle="yes">-/-</italic></sup> mice after gene augmentation therapy.</title><p><bold>A</bold> Representative scotopic (dark-adapted) ERG waveforms in response to a series of flashes from wild-type (left), untreated <italic toggle="yes">Cnga1</italic><sup><italic toggle="yes">-/-</italic></sup> (middle), and treated <italic toggle="yes">Cnga1</italic><sup><italic toggle="yes">-/-</italic></sup> mice (right) at 9 months of age. <bold>B</bold> Quantification of a-wave amplitudes of untreated and treated <italic toggle="yes">Cnga1</italic><sup>-/-</sup> mice at 9 months of age. Mean&#8201;&#177;&#8201;SEM. **<italic toggle="yes">P</italic>&#8201;&lt;&#8201;0.01; two-way ANOVA with &#352;&#237;d&#225;k&#8217;s multiple comparisons. <italic toggle="yes">P</italic> values are 0.008 at 0, 0.002 at 0.5, and 0.0034 at 1 light intensities. <bold>C</bold> Quantification of scotopic b-wave amplitudes of untreated and treated <italic toggle="yes">Cnga1</italic><sup>-/-</sup> mice at 9 months of age. Mean&#8201;&#177;&#8201;SEM. *<italic toggle="yes">P</italic>&#8201;&lt;&#8201;0.05, **<italic toggle="yes">P</italic>&#8201;&lt;&#8201;0.01, ***<italic toggle="yes">P</italic>&#8201;&lt;&#8201;0.001; two-way ANOVA with &#352;&#237;d&#225;k&#8217;s multiple comparisons. <italic toggle="yes">P</italic> values are 0.0208 at &#8722;1.5, 0.0067 at &#8722;1, 0.0017 at &#8722;0.5, 0.0003 at 0, and &lt;0.0001 at higher light intensities. The numbers of eyes were as follows: treated <italic toggle="yes">Cnga1</italic><sup><italic toggle="yes">-/-</italic></sup>, <italic toggle="yes">n</italic>&#8201;=&#8201;10; untreated <italic toggle="yes">Cnga1</italic><sup><italic toggle="yes">-/-</italic></sup>, <italic toggle="yes">n</italic>&#8201;=&#8201;4. <bold>D</bold> Representative photopic (light-adapted) ERG waveforms in response to a series of flashes from wild-type (left), untreated <italic toggle="yes">Cnga1</italic><sup><italic toggle="yes">-/-</italic></sup> (middle), and treated <italic toggle="yes">Cnga1</italic><sup><italic toggle="yes">-/-</italic></sup> mice (right) at 9 months of age. <bold>E</bold> Quantification of photopic b-wave amplitudes of untreated and treated <italic toggle="yes">Cnga1</italic><sup>-/-</sup> mice at 9 months of age. Mean&#8201;&#177;&#8201;SEM. ***<italic toggle="yes">P</italic>&#8201;&lt;&#8201;0.001; two-way ANOVA with &#352;&#237;d&#225;k&#8217;s multiple comparisons. <italic toggle="yes">P</italic> values are 0.0807 at &#8722;1, 0.0567 at 0, and &lt;0.0001 at higher light intensities.</p></caption><graphic id="d33e1379" position="float" orientation="portrait" xlink:href="43856_2025_1108_Fig6_HTML.jpg"/></fig></p></sec><sec id="Sec20"><title>Gene augmentation therapy improves vision-guided behavior in Cnga1<sup>-/-</sup> mice</title><p id="Par35">Having demonstrated that our gene augmentation strategy restored retinal function and prolonged photoreceptor survival in <italic toggle="yes">Cnga1</italic><sup><italic toggle="yes">-/-</italic></sup> mice, we were curious as to whether the improvement at the retinal level eventually translated to the improvement in the behavioral level. To answer this question, we utilized the water maze test under dim-light conditions. In this vision-guided behavior assay, 9-month-old mice were trained to locate a visible platform over three consecutive days (D1-D3). The time it took for the mice to find the platform was recorded as &#8220;escape latency&#8221; with a time limit set at one minute.</p><p id="Par36">The representative swimming paths on D3 are illustrated in Fig.&#160;<xref rid="Fig7" ref-type="fig">7A</xref>. During the three-day period, the learning curves of wild-type and treated <italic toggle="yes">Cnga1</italic><sup><italic toggle="yes">-/-</italic></sup> mice closely paralleled each other (Fig.&#160;<xref rid="Fig7" ref-type="fig">7B, C, D</xref>). The success rate of both groups rapidly approached nearly 100% on D2, accompanied by a gradual decrease in escape latency (Fig.&#160;<xref rid="Fig7" ref-type="fig">7B</xref>). In contrast, untreated <italic toggle="yes">Cnga1</italic><sup><italic toggle="yes">-/-</italic></sup> mice often struggled to reach the platform within one minute, and therefore the escape latency showed no significant change over time (Fig.&#160;<xref rid="Fig7" ref-type="fig">7B, C</xref>).<fig id="Fig7" position="float" orientation="portrait"><label>Fig. 7</label><caption><title>Improvement of vision-guided behavior in 9-month-old <italic toggle="yes">Cnga1</italic><sup><italic toggle="yes">-/-</italic></sup> mice after gene augmentation therapy.</title><p><bold>A</bold> Representative swimming route on day 3. <bold>B</bold> Quantification of the success rate to locate the platform within 1&#8201;minute from day 1 to day 3. **<italic toggle="yes">P</italic>&#8201;&lt;&#8201;0.01, two-way ANOVA with Tukey&#8217;s multiple comparisons. Asterisks indicate a significant difference between treated and untreated <italic toggle="yes">Cnga1</italic><sup><italic toggle="yes">-/-</italic></sup> mice at day 3. <italic toggle="yes">P</italic> value is 0.0026. <bold>C</bold> Quantification of the escape latency from day 1 to day 3. ***<italic toggle="yes">P</italic>&#8201;&lt;&#8201;0.001, two-way ANOVA with Tukey&#8217;s multiple comparisons. Asterisks indicate a significant difference between treated and untreated <italic toggle="yes">Cnga1</italic><sup><italic toggle="yes">-/-</italic></sup> mice at day 3. <italic toggle="yes">P</italic> value is &lt;0.0001. <bold>D</bold> Quantification of the total path length from day 1 to day 3. ***<italic toggle="yes">P</italic>&#8201;&lt;&#8201;0.001, two-way ANOVA with Tukey&#8217;s multiple comparisons. Asterisks indicate a significant difference between treated and untreated <italic toggle="yes">Cnga1</italic><sup><italic toggle="yes">-/-</italic></sup> mice on day 3. <italic toggle="yes">P</italic> value is &lt;0.0001. The numbers of mice were as follows: wild-type, <italic toggle="yes">n</italic>&#8201;=&#8201;4; untreated <italic toggle="yes">Cnga1</italic><sup><italic toggle="yes">-/-</italic></sup>, <italic toggle="yes">n</italic>&#8201;=&#8201;4; treated <italic toggle="yes">Cnga1</italic><sup><italic toggle="yes">-/-</italic></sup>, <italic toggle="yes">n</italic>&#8201;=&#8201;5. Each mouse completed 8 trials per day.</p></caption><graphic id="d33e1506" position="float" orientation="portrait" xlink:href="43856_2025_1108_Fig7_HTML.jpg"/></fig></p><p id="Par37">We also analyzed the path length (Fig.&#160;<xref rid="Fig7" ref-type="fig">7D</xref>) and identified a pattern similar to that observed in escape latency. Over the training period, the path length of wild-type and treated <italic toggle="yes">Cnga1</italic><sup><italic toggle="yes">-/-</italic></sup> mice decreased progressively, whereas it remained high for untreated <italic toggle="yes">Cnga1</italic><sup><italic toggle="yes">-/-</italic></sup> mice. Together, these observations indicate that the restored retinal function is processed properly in treated <italic toggle="yes">Cnga1</italic><sup><italic toggle="yes">-/-</italic></sup> mice, resulting in improved vision-guided behavior.</p></sec><sec id="Sec21"><title>Gene augmentation therapy restores the expression of rod phototransduction-related genes in Cnga1<sup>-/-</sup> mice</title><p id="Par38">To evaluate the transcriptional rescue effects of gene augmentation therapy on photoreceptors, we conducted RNA sequencing (RNA-seq) analysis of retinas from 3-month-old wild-type, untreated <italic toggle="yes">Cnga1</italic><sup><italic toggle="yes">-/-</italic></sup>, and treated <italic toggle="yes">Cnga1</italic><sup><italic toggle="yes">-/-</italic></sup> mice. As expected, untreated <italic toggle="yes">Cnga1</italic><sup><italic toggle="yes">-/-</italic></sup> mice exhibited significant downregulation of rod-specific genes compared to wild-type controls (Fig.&#160;<xref rid="Fig8" ref-type="fig">8A</xref>). Gene Set Enrichment Analysis (GSEA) revealed substantial repression of gene sets associated with phototransduction and photoreceptor cell maintenance in untreated retinas (Fig.&#160;<xref rid="Fig8" ref-type="fig">8C</xref>). In contrast, gene augmentation therapy restored the expression of rod-specific genes (Fig.&#160;<xref rid="Fig8" ref-type="fig">8B</xref>), and re-enriched phototransduction and photoreceptor cell maintenance pathways (Fig.&#160;<xref rid="Fig8" ref-type="fig">8D</xref>). We validated these findings using quantitative real-time PCR (qPCR). Treated mice showed significant mRNA recovery of <italic toggle="yes">Cnga1</italic> and other key rod phototransduction genes, including <italic toggle="yes">Rho</italic>, <italic toggle="yes">Pde6a</italic>, <italic toggle="yes">Pde6b</italic>, <italic toggle="yes">Pde6g</italic>, <italic toggle="yes">Cngb1</italic>, <italic toggle="yes">Gucy2e</italic>, <italic toggle="yes">Gucy2f</italic>, <italic toggle="yes">Guca1a</italic>, and <italic toggle="yes">Guca1b</italic> (Fig.&#160;<xref rid="Fig8" ref-type="fig">8E</xref>). Collectively, these results demonstrate that gene augmentation therapy successfully preserves the transcriptional program of rod phototransduction in <italic toggle="yes">Cnga1</italic><sup><italic toggle="yes">-/-</italic></sup> mice.<fig id="Fig8" position="float" orientation="portrait"><label>Fig. 8</label><caption><title>RNA-seq of treated retinas revealed the therapeutic rescue of phototransduction genes in 3-month-old <italic toggle="yes">Cnga1&#8315;/&#8315;</italic> mice.</title><p><bold>A</bold> Volcano plot of differentially expressed genes between wild type and untreated retinas (|log2(fold change) |)&gt; 0.58 and p&#8201;&lt;&#8201;0.05. <bold>B</bold> Volcano plot of differentially expressed genes between untreated and treated retinas (|log2(fold change) |)&gt; 0.58 and p&#8201;&lt;&#8201;0.05. <bold>C</bold> GSEA revealed significant downregulation of phototransduction and photoreceptor cell maintenance pathways in untreated versus wild-type retinas. <bold>D</bold> GSEA showed upregulation of phototransduction and photoreceptor cell maintenance pathways in treated versus untreated retinas. <bold>E</bold> Relative expression levels of rod phototransduction-related genes in wild type, untreated, and treated retinas, as measured by real-time qPCR (<italic toggle="yes">n</italic>&#8201;=&#8201;4). mRNA levels were normalized to <italic toggle="yes">Gapdh</italic> expression and presented as Mean&#8201;&#177;&#8201;SEM. Statistical significance determined by one-way ANOVA with Tukey&#8217;s post hoc test.</p></caption><graphic id="d33e1642" position="float" orientation="portrait" xlink:href="43856_2025_1108_Fig8_HTML.jpg"/></fig></p></sec></sec><sec id="Sec22" sec-type="discussion"><title>Discussion</title><p id="Par39">The rod CNG channel is composed of three CNGA1 and one CNGB1 subunit<sup><xref ref-type="bibr" rid="CR1">1</xref>,<xref ref-type="bibr" rid="CR35">35</xref></sup>. Biallelic mutations in either <italic toggle="yes">CNGA1</italic> or <italic toggle="yes">CNGB1</italic> result in progressive rod-cone degeneration known as RP<sup><xref ref-type="bibr" rid="CR18">18</xref>,<xref ref-type="bibr" rid="CR19">19</xref></sup>. We are interested in <italic toggle="yes">CNGA1</italic>-RP for two reasons. First, the prevalence of <italic toggle="yes">CNGA1</italic>-RP shows dramatically higher in Asian countries<sup><xref ref-type="bibr" rid="CR8">8</xref>,<xref ref-type="bibr" rid="CR10">10</xref></sup> compared to other regions<sup><xref ref-type="bibr" rid="CR4">4</xref>&#8211;<xref ref-type="bibr" rid="CR7">7</xref>,<xref ref-type="bibr" rid="CR9">9</xref>,<xref ref-type="bibr" rid="CR15">15</xref></sup> (appropriately 4 times). Second, successful proof-of-concept studies for AAV-based gene augmentation therapy have been reported in animal models of <italic toggle="yes">CNGB1</italic>-RP<sup><xref ref-type="bibr" rid="CR22">22</xref>,<xref ref-type="bibr" rid="CR38">38</xref>&#8211;<xref ref-type="bibr" rid="CR40">40</xref></sup>. Considering the close relationship of <italic toggle="yes">CNGA1</italic> and <italic toggle="yes">CNGB1</italic>, we hypothesized that AAV-mediated expression of CNGA1 would be a feasible approach for the treatment of <italic toggle="yes">CNGA1</italic>-RP. To test this hypothesis, we previously developed a <italic toggle="yes">Cnga1</italic><sup><italic toggle="yes">-/-</italic></sup> mouse model<sup><xref ref-type="bibr" rid="CR20">20</xref></sup>. In this study, we first performed a detailed phenotypic analysis of this model with OCT and ERG techniques. <italic toggle="yes">Cnga1</italic><sup><italic toggle="yes">-/-</italic></sup> mice exhibited a progressive loss of photoreceptors, which was almost complete by the age of 6 months. Scotopic ERGs indicated a loss of rod-mediated function, as expected, since the CNG channel is the final target of the light-activated signaling pathway. Interestingly, we observed a &#8216;supernormal&#8217; period of cone function in <italic toggle="yes">Cnga1</italic><sup><italic toggle="yes">-/-</italic></sup> mice during the first two months postnatal. Nonetheless, with the progression of cone degeneration, both scotopic and photopic ERG responses deteriorated. By 6 months of age, ERG responses diminished to a negligible level. Subsequently, we initiated gene augmentation therapy based on the understanding of the above natural history data. We treated <italic toggle="yes">Cnga1</italic><sup><italic toggle="yes">-/-</italic></sup> mice at postnatal day 14, a timepoint prior to major loss of rod photoreceptors, and followed the treated mice to the end-stage of disease at 9 months of age. The therapeutic vector (AAV8-<italic toggle="yes">hRHO</italic>-<italic toggle="yes">mCnga1</italic>) delivered to the subretinal space of <italic toggle="yes">Cnga1</italic><sup><italic toggle="yes">-/-</italic></sup> mice restored rod-mediated retinal function and vision-guided behavior for at least 8.5 months post-treatment. Immunohistochemistry showed that CNGA1 was successfully expressed and was correctly trafficked to the outer segments, where the native rod CNG channel is located. In vivo OCT imaging as well as ex vivo histological analysis demonstrated long-term preservation of retinal structure. To our knowledge, the present study is the first report of phenotypic rescue with AAV-based gene augmentation therapy in an animal model of <italic toggle="yes">CNGA1</italic>-RP.</p><p id="Par40">The availability of suitable disease models has been instrumental in translating any promising treatments to the clinic. Apart from our <italic toggle="yes">Cnga1</italic><sup><italic toggle="yes">-/-</italic></sup> mouse model, four other models were reported in the literature. The first <italic toggle="yes">CNGA1</italic>-RP mouse model was generated by overexpression of an 890&#8201;bp <italic toggle="yes">Cnga1</italic> antisense mRNA more than two decades ago<sup><xref ref-type="bibr" rid="CR41">41</xref></sup>. This transgenic mouse showed slight photoreceptor degeneration at 12 months of age<sup><xref ref-type="bibr" rid="CR41">41</xref></sup>. However, functional analysis has not been reported so far. In 2015, a spontaneously occurring dog model was identified with 4-bp deletion in exon 9 (c.1752_1755delAACT) of <italic toggle="yes">Cnga1</italic> gene<sup><xref ref-type="bibr" rid="CR42">42</xref></sup>, a detailed description of the retinal phenotype is still pending. More recently, a mouse model was re-derived from the sperm samples of ENU (N-ethyl-N-nitrosourea) mutagenesis repository<sup><xref ref-type="bibr" rid="CR43">43</xref></sup>. The ENU mouse carries a c.1526&#8201;A&#8201;&gt;&#8201;G mutation in <italic toggle="yes">Cnga1</italic>, resulting in Y509C in the cyclic nucleotide-binding domain of CNGA1 protein. This Y509C mutation leads to a complete loss of CNGA1 protein expression<sup><xref ref-type="bibr" rid="CR43">43</xref></sup>. Consequently, rod-driven ERG responses were diminished in the <italic toggle="yes">Cnga1</italic><sup>Y509C/Y509C</sup> mouse, a phenotype similar to that observed in our <italic toggle="yes">Cnga1</italic><sup><italic toggle="yes">-/-</italic></sup> mouse. However, the progression rate of photoreceptor degeneration in <italic toggle="yes">Cnga1</italic><sup>Y509C/Y509C</sup> mice is much slower than that in <italic toggle="yes">Cnga1</italic><sup><italic toggle="yes">-/-</italic></sup> mice. At 6 months of age, most photoreceptor nuclei were lost in <italic toggle="yes">Cnga1</italic><sup><italic toggle="yes">-/-</italic></sup> mice, whereas 40% photoreceptors remained in <italic toggle="yes">Cnga1</italic><sup>Y509C/Y509C</sup> mice<sup><xref ref-type="bibr" rid="CR43">43</xref></sup>. The underlying reason for the difference in progression rate is unclear and warrants further investigation. Considering that CNGA1 functions with CNGB1 as a heterotetramer, we recently developed a patient-induced pluripotent stem cell (iPSC) line to facilitate the testing of species-matched gene augmentation therapy<sup><xref ref-type="bibr" rid="CR44">44</xref></sup>. Together, these disease models provide us with valuable platforms for understanding the disease mechanisms and tools to evaluate therapeutic strategies for <italic toggle="yes">CNGA1</italic>-RP.</p><p id="Par41">This work demonstrates a proof-of-concept for the treatment of <italic toggle="yes">CNGA1</italic>-RP using AAV-based gene augmentation therapy. Further efforts are needed before this treatment can be translated into the clinic. Firstly, the natural history of patients with <italic toggle="yes">CNGA1</italic>-RP should be systematically evaluated. This will not only allow for a more precise comparison of human phenotypes with those of animal models but also may provide suitable biomarkers of disease progression as well as potential outcome measures for future clinical trials<sup><xref ref-type="bibr" rid="CR45">45</xref></sup>. Furthermore, further optimization of the vector, both in terms of the vector construct and optimal dose, is warranted. Finally, it will be essential to understand the efficacy of therapy applied at different disease stages<sup><xref ref-type="bibr" rid="CR46">46</xref>&#8211;<xref ref-type="bibr" rid="CR49">49</xref></sup>. In the current study, we treated <italic toggle="yes">Cnga1</italic><sup><italic toggle="yes">-/-</italic></sup> mice at an early stage of the disease to assess the maximal potential of gene augmentation therapy; however, patients with RP are often diagnosed at a later stage of the disease. It is, therefore, important to determine the therapeutic time window in future studies. With these further efforts, we believe that gene augmentation therapy will, for the first time, provide a therapeutic intervention for patients with <italic toggle="yes">CNGA1</italic>-RP.</p></sec><sec id="Sec23" sec-type="supplementary-material"><title>Supplementary information</title><p>
<supplementary-material content-type="local-data" id="MOESM1" position="float" orientation="portrait"><media xlink:href="43856_2025_1108_MOESM1_ESM.pdf" position="float" orientation="portrait"><caption><p>Supplementary Information</p></caption></media></supplementary-material>
<supplementary-material content-type="local-data" id="MOESM2" position="float" orientation="portrait"><media xlink:href="43856_2025_1108_MOESM2_ESM.pdf" position="float" orientation="portrait"><caption><p>Description of Additional Supplementary files</p></caption></media></supplementary-material>
<supplementary-material content-type="local-data" id="MOESM3" position="float" orientation="portrait"><media xlink:href="43856_2025_1108_MOESM3_ESM.zip" position="float" orientation="portrait"><caption><p>Supplementary Data 1</p></caption></media></supplementary-material>
<supplementary-material content-type="local-data" id="MOESM4" position="float" orientation="portrait"><media xlink:href="43856_2025_1108_MOESM4_ESM.pdf" position="float" orientation="portrait"><caption><p>reporting summary</p></caption></media></supplementary-material>
</p></sec></body><back><fn-group><fn><p><bold>Publisher&#8217;s note</bold> Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn><fn><p>These authors contributed equally: Yidong Wu, Tianyuan Zhao, Yazhi Wang, Ting Zhang, Chenyue Hang.</p></fn></fn-group><sec><title>Supplementary information</title><p>The online version contains supplementary material available at 10.1038/s43856-025-01108-x.</p></sec><ack><title>Acknowledgements</title><p>This work was supported by the Shanghai Sailing Program (24YF2734000 to Yidong Wu), Natural Science Foundation of Shanghai (24ZR1458800 to Xiaoling Wan), National Natural Science Foundation of China (U22A20311 and 82388101 to Xiaodong Sun), and Science and Technology Commission of Shanghai Municipality (23J41900200 to Xiaodong Sun).</p></ack><notes notes-type="author-contribution"><title>Author contributions</title><p>Yi.W., X.W., F.W., and X.S. conceived and designed the research. Yi.W., Tia.Z., Yaz.W., and Tin.Z. designed, performed, and analyzed the in vivo experiments. C.H. performed immunohistochemistry experiments. Yaf.W., Y.L., Z.C., and J.C. performed RNA sequencing. T.L., J.S., H.J., and L.Z. contributed to data collection and interpretation. Yi.W. and X.W. wrote the manuscript. All authors read and approved the final manuscript.</p></notes><notes notes-type="peer-review"><title>Peer review</title><sec id="FPar1"><title>Peer review information</title><p id="Par42"><italic toggle="yes">Communications Medicine</italic> thanks Michelle McClements and the other, anonymous, reviewer(s) for their contribution to the peer review of this work.</p></sec></notes><notes notes-type="data-availability"><title>Data availability</title><p>The numerical data plotted (source data) in the graphs are in Supplementary Data. Raw data of RNA-seq were deposited in the Sequence Read Archive database (accession number PRJNA1214527). All other data are available from the corresponding author on reasonable request.</p></notes><notes id="FPar2" notes-type="COI-statement"><title>Competing interests</title><p id="Par43">F.W. is an equity owner of Innostellar Biotherapeutics, a company developing human gene therapies. The remaining authors declare no competing interests.</p></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><citation-alternatives><element-citation id="ec-CR1" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kaupp</surname><given-names>UB</given-names></name><name name-style="western"><surname>Seifert</surname><given-names>R</given-names></name></person-group><article-title>Cyclic nucleotide-gated ion channels</article-title><source>Physiol. Rev.</source><year>2002</year><volume>82</volume><fpage>769</fpage><lpage>824</lpage><pub-id pub-id-type="pmid">12087135</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1152/physrev.00008.2002</pub-id></element-citation><mixed-citation id="mc-CR1" publication-type="journal">Kaupp, U. B. &amp; Seifert, R. Cyclic nucleotide-gated ion channels. <italic toggle="yes">Physiol. Rev.</italic><bold>82</bold>, 769&#8211;824 (2002).<pub-id pub-id-type="pmid">12087135</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1152/physrev.00008.2002</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR2"><label>2.</label><citation-alternatives><element-citation id="ec-CR2" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Power</surname><given-names>M</given-names></name><etal/></person-group><article-title>Cellular mechanisms of hereditary photoreceptor degeneration - Focus on cGMP</article-title><source>Prog. Retin. Eye Res.</source><year>2020</year><volume>74</volume><fpage>100772</fpage><pub-id pub-id-type="pmid">31374251</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.preteyeres.2019.07.005</pub-id></element-citation><mixed-citation id="mc-CR2" publication-type="journal">Power, M. et al. Cellular mechanisms of hereditary photoreceptor degeneration - Focus on cGMP. <italic toggle="yes">Prog. Retin. Eye Res.</italic><bold>74</bold>, 100772 (2020).<pub-id pub-id-type="pmid">31374251</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.preteyeres.2019.07.005</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR3"><label>3.</label><citation-alternatives><element-citation id="ec-CR3" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Arshavsky</surname><given-names>VY</given-names></name><name name-style="western"><surname>Lamb</surname><given-names>TD</given-names></name><name name-style="western"><surname>Pugh</surname><given-names>EN</given-names><suffix>Jr</suffix></name></person-group><article-title>G proteins and phototransduction</article-title><source>Annu. Rev. Physiol.</source><year>2002</year><volume>64</volume><fpage>153</fpage><lpage>187</lpage><pub-id pub-id-type="pmid">11826267</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1146/annurev.physiol.64.082701.102229</pub-id></element-citation><mixed-citation id="mc-CR3" publication-type="journal">Arshavsky, V. Y., Lamb, T. D. &amp; Pugh, E. N. Jr G proteins and phototransduction. <italic toggle="yes">Annu. Rev. Physiol.</italic><bold>64</bold>, 153&#8211;187 (2002).<pub-id pub-id-type="pmid">11826267</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1146/annurev.physiol.64.082701.102229</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR4"><label>4.</label><citation-alternatives><element-citation id="ec-CR4" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dryja</surname><given-names>TP</given-names></name><etal/></person-group><article-title>Mutations in the gene encoding the alpha subunit of the rod cGMP-gated channel in autosomal recessive retinitis pigmentosa</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>1995</year><volume>92</volume><fpage>10177</fpage><lpage>10181</lpage><pub-id pub-id-type="pmid">7479749</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1073/pnas.92.22.10177</pub-id><pub-id pub-id-type="pmcid">PMC40759</pub-id></element-citation><mixed-citation id="mc-CR4" publication-type="journal">Dryja, T. P. et al. Mutations in the gene encoding the alpha subunit of the rod cGMP-gated channel in autosomal recessive retinitis pigmentosa. <italic toggle="yes">Proc. Natl. Acad. Sci. USA</italic><bold>92</bold>, 10177&#8211;10181 (1995).<pub-id pub-id-type="pmid">7479749</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1073/pnas.92.22.10177</pub-id><pub-id pub-id-type="pmcid">PMC40759</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR5"><label>5.</label><citation-alternatives><element-citation id="ec-CR5" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hartong</surname><given-names>DT</given-names></name><name name-style="western"><surname>Berson</surname><given-names>EL</given-names></name><name name-style="western"><surname>Dryja</surname><given-names>TP</given-names></name></person-group><article-title>Retinitis pigmentosa</article-title><source>Lancet</source><year>2006</year><volume>368</volume><fpage>1795</fpage><lpage>1809</lpage><pub-id pub-id-type="pmid">17113430</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0140-6736(06)69740-7</pub-id></element-citation><mixed-citation id="mc-CR5" publication-type="journal">Hartong, D. T., Berson, E. L. &amp; Dryja, T. P. Retinitis pigmentosa. <italic toggle="yes">Lancet</italic><bold>368</bold>, 1795&#8211;1809 (2006).<pub-id pub-id-type="pmid">17113430</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0140-6736(06)69740-7</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR6"><label>6.</label><citation-alternatives><element-citation id="ec-CR6" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>X</given-names></name><etal/></person-group><article-title>Targeted sequencing of 179 genes associated with hereditary retinal dystrophies and 10 candidate genes identifies novel and known mutations in patients with various retinal diseases</article-title><source>Invest. Ophthalmol. Vis. Sci.</source><year>2013</year><volume>54</volume><fpage>2186</fpage><lpage>2197</lpage><pub-id pub-id-type="pmid">23462753</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1167/iovs.12-10967</pub-id></element-citation><mixed-citation id="mc-CR6" publication-type="journal">Chen, X. et al. Targeted sequencing of 179 genes associated with hereditary retinal dystrophies and 10 candidate genes identifies novel and known mutations in patients with various retinal diseases. <italic toggle="yes">Invest. Ophthalmol. Vis. Sci.</italic><bold>54</bold>, 2186&#8211;2197 (2013).<pub-id pub-id-type="pmid">23462753</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1167/iovs.12-10967</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR7"><label>7.</label><citation-alternatives><element-citation id="ec-CR7" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hanany</surname><given-names>M</given-names></name><name name-style="western"><surname>Rivolta</surname><given-names>C</given-names></name><name name-style="western"><surname>Sharon</surname><given-names>D</given-names></name></person-group><article-title>Worldwide carrier frequency and genetic prevalence of autosomal recessive inherited retinal diseases</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2020</year><volume>117</volume><fpage>2710</fpage><lpage>2716</lpage><pub-id pub-id-type="pmid">31964843</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1073/pnas.1913179117</pub-id><pub-id pub-id-type="pmcid">PMC7007541</pub-id></element-citation><mixed-citation id="mc-CR7" publication-type="journal">Hanany, M., Rivolta, C. &amp; Sharon, D. Worldwide carrier frequency and genetic prevalence of autosomal recessive inherited retinal diseases. <italic toggle="yes">Proc. Natl. Acad. Sci. USA</italic><bold>117</bold>, 2710&#8211;2716 (2020).<pub-id pub-id-type="pmid">31964843</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1073/pnas.1913179117</pub-id><pub-id pub-id-type="pmcid">PMC7007541</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR8"><label>8.</label><citation-alternatives><element-citation id="ec-CR8" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gao</surname><given-names>FJ</given-names></name><etal/></person-group><article-title>Genetic anD CLINICAL FINDINGS IN A LARGE COHORT OF CHINESE PATIENTS WITH SUSPECTEd Retinitis Pigmentosa</article-title><source>Ophthalmology</source><year>2019</year><volume>126</volume><fpage>1549</fpage><lpage>1556</lpage><pub-id pub-id-type="pmid">31054281</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ophtha.2019.04.038</pub-id></element-citation><mixed-citation id="mc-CR8" publication-type="journal">Gao, F. J. et al. Genetic anD CLINICAL FINDINGS IN A LARGE COHORT OF CHINESE PATIENTS WITH SUSPECTEd Retinitis Pigmentosa. <italic toggle="yes">Ophthalmology</italic><bold>126</bold>, 1549&#8211;1556 (2019).<pub-id pub-id-type="pmid">31054281</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ophtha.2019.04.038</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR9"><label>9.</label><citation-alternatives><element-citation id="ec-CR9" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Paloma</surname><given-names>E</given-names></name><etal/></person-group><article-title>Novel homozygous mutation in the alpha subunit of the rod cGMP gated channel (CNGA1) in two Spanish sibs affected with autosomal recessive retinitis pigmentosa</article-title><source>J. Med. Genet.</source><year>2002</year><volume>39</volume><fpage>E66</fpage><pub-id pub-id-type="pmid">12362048</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/jmg.39.10.e66</pub-id><pub-id pub-id-type="pmcid">PMC1734976</pub-id></element-citation><mixed-citation id="mc-CR9" publication-type="journal">Paloma, E. et al. Novel homozygous mutation in the alpha subunit of the rod cGMP gated channel (CNGA1) in two Spanish sibs affected with autosomal recessive retinitis pigmentosa. <italic toggle="yes">J. Med. Genet.</italic><bold>39</bold>, E66 (2002).<pub-id pub-id-type="pmid">12362048</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/jmg.39.10.e66</pub-id><pub-id pub-id-type="pmcid">PMC1734976</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR10"><label>10.</label><citation-alternatives><element-citation id="ec-CR10" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Katagiri</surname><given-names>S</given-names></name><etal/></person-group><article-title>Whole exome analysis identifies frequent CNGA1 mutations in Japanese population with autosomal recessive retinitis pigmentosa</article-title><source>PLoS One</source><year>2014</year><volume>9</volume><fpage>e108721</fpage><pub-id pub-id-type="pmid">25268133</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pone.0108721</pub-id><pub-id pub-id-type="pmcid">PMC4182560</pub-id></element-citation><mixed-citation id="mc-CR10" publication-type="journal">Katagiri, S. et al. Whole exome analysis identifies frequent CNGA1 mutations in Japanese population with autosomal recessive retinitis pigmentosa. <italic toggle="yes">PLoS One</italic><bold>9</bold>, e108721 (2014).<pub-id pub-id-type="pmid">25268133</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pone.0108721</pub-id><pub-id pub-id-type="pmcid">PMC4182560</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR11"><label>11.</label><citation-alternatives><element-citation id="ec-CR11" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>Q</given-names></name><etal/></person-group><article-title>Autosomal recessive retinitis pigmentosa in a Pakistani family mapped to CNGA1 with identification of a novel mutation</article-title><source>Mol. Vis.</source><year>2004</year><volume>10</volume><fpage>884</fpage><lpage>889</lpage><pub-id pub-id-type="pmid">15570217</pub-id></element-citation><mixed-citation id="mc-CR11" publication-type="journal">Zhang, Q. et al. Autosomal recessive retinitis pigmentosa in a Pakistani family mapped to CNGA1 with identification of a novel mutation. <italic toggle="yes">Mol. Vis.</italic><bold>10</bold>, 884&#8211;889 (2004).<pub-id pub-id-type="pmid">15570217</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR12"><label>12.</label><citation-alternatives><element-citation id="ec-CR12" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ye</surname><given-names>Z</given-names></name><etal/></person-group><article-title>Case Report: The First Reported Concurrence of Wilson Disease and Bilateral Retinitis Pigmentosa</article-title><source>Front. Med.</source><year>2022</year><volume>9</volume><fpage>877752</fpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fmed.2022.877752</pub-id><pub-id pub-id-type="pmcid">PMC9098211</pub-id><pub-id pub-id-type="pmid">35573004</pub-id></element-citation><mixed-citation id="mc-CR12" publication-type="journal">Ye, Z. et al. Case Report: The First Reported Concurrence of Wilson Disease and Bilateral Retinitis Pigmentosa. <italic toggle="yes">Front. Med.</italic><bold>9</bold>, 877752 (2022).<pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fmed.2022.877752</pub-id><pub-id pub-id-type="pmcid">PMC9098211</pub-id><pub-id pub-id-type="pmid">35573004</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR13"><label>13.</label><citation-alternatives><element-citation id="ec-CR13" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gao</surname><given-names>Q</given-names></name><etal/></person-group><article-title>A novel CNGA1 GENE MUtation (c.G622A) of autosomal recessive Retinitis Pigmentosa leads to the CNGA1 protein reduction on membrane</article-title><source>Biochem. Genet.</source><year>2019</year><volume>57</volume><fpage>540</fpage><lpage>554</lpage><pub-id pub-id-type="pmid">30652268</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s10528-019-09907-3</pub-id></element-citation><mixed-citation id="mc-CR13" publication-type="journal">Gao, Q. et al. A novel CNGA1 GENE MUtation (c.G622A) of autosomal recessive Retinitis Pigmentosa leads to the CNGA1 protein reduction on membrane. <italic toggle="yes">Biochem. Genet.</italic><bold>57</bold>, 540&#8211;554 (2019).<pub-id pub-id-type="pmid">30652268</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s10528-019-09907-3</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR14"><label>14.</label><citation-alternatives><element-citation id="ec-CR14" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>M</given-names></name><name name-style="western"><surname>Gan</surname><given-names>D</given-names></name><name name-style="western"><surname>Huang</surname><given-names>X</given-names></name><name name-style="western"><surname>Xu</surname><given-names>G</given-names></name></person-group><article-title>Novel compound heterozygous mutations in CNGA1in a Chinese family affected with autosomal recessive retinitis pigmentosa by targeted sequencing</article-title><source>BMC Ophthalmol.</source><year>2016</year><volume>16</volume><fpage>101</fpage><pub-id pub-id-type="pmid">27391953</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12886-016-0281-6</pub-id><pub-id pub-id-type="pmcid">PMC4938971</pub-id></element-citation><mixed-citation id="mc-CR14" publication-type="journal">Wang, M., Gan, D., Huang, X. &amp; Xu, G. Novel compound heterozygous mutations in CNGA1in a Chinese family affected with autosomal recessive retinitis pigmentosa by targeted sequencing. <italic toggle="yes">BMC Ophthalmol.</italic><bold>16</bold>, 101 (2016).<pub-id pub-id-type="pmid">27391953</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12886-016-0281-6</pub-id><pub-id pub-id-type="pmcid">PMC4938971</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR15"><label>15.</label><citation-alternatives><element-citation id="ec-CR15" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jin</surname><given-names>X</given-names></name><etal/></person-group><article-title>Novel compound heterozygous mutation in the CNGA1 gene underlie autosomal recessive retinitis pigmentosa in a Chinese family</article-title><source>Biosci. Rep.</source><year>2016</year><volume>36</volume><fpage>e00289</fpage><pub-id pub-id-type="pmid">26802146</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1042/BSR20150131</pub-id><pub-id pub-id-type="pmcid">PMC4725244</pub-id></element-citation><mixed-citation id="mc-CR15" publication-type="journal">Jin, X. et al. Novel compound heterozygous mutation in the CNGA1 gene underlie autosomal recessive retinitis pigmentosa in a Chinese family. <italic toggle="yes">Biosci. Rep.</italic><bold>36</bold>, e00289 (2016).<pub-id pub-id-type="pmid">26802146</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1042/BSR20150131</pub-id><pub-id pub-id-type="pmcid">PMC4725244</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR16"><label>16.</label><citation-alternatives><element-citation id="ec-CR16" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Saito</surname><given-names>K</given-names></name><etal/></person-group><article-title>A case of retinitis pigmentosa homozygous for a rare CNGA1 causal variant</article-title><source>Sci. Rep.</source><year>2021</year><volume>11</volume><fpage>4681</fpage><pub-id pub-id-type="pmid">33633220</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41598-021-84098-9</pub-id><pub-id pub-id-type="pmcid">PMC7907121</pub-id></element-citation><mixed-citation id="mc-CR16" publication-type="journal">Saito, K. et al. A case of retinitis pigmentosa homozygous for a rare CNGA1 causal variant. <italic toggle="yes">Sci. Rep.</italic><bold>11</bold>, 4681 (2021).<pub-id pub-id-type="pmid">33633220</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41598-021-84098-9</pub-id><pub-id pub-id-type="pmcid">PMC7907121</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR17"><label>17.</label><citation-alternatives><element-citation id="ec-CR17" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Russell</surname><given-names>S</given-names></name><etal/></person-group><article-title>Efficacy and safety of voretigene neparvovec (AAV2-hRPE65v2) in patients with RPE65-mediated inherited retinal dystrophy: a randomised, controlled, open-label, phase 3 trial</article-title><source>Lancet</source><year>2017</year><volume>390</volume><fpage>849</fpage><lpage>860</lpage><pub-id pub-id-type="pmid">28712537</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0140-6736(17)31868-8</pub-id><pub-id pub-id-type="pmcid">PMC5726391</pub-id></element-citation><mixed-citation id="mc-CR17" publication-type="journal">Russell, S. et al. Efficacy and safety of voretigene neparvovec (AAV2-hRPE65v2) in patients with RPE65-mediated inherited retinal dystrophy: a randomised, controlled, open-label, phase 3 trial. <italic toggle="yes">Lancet</italic><bold>390</bold>, 849&#8211;860 (2017).<pub-id pub-id-type="pmid">28712537</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0140-6736(17)31868-8</pub-id><pub-id pub-id-type="pmcid">PMC5726391</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR18"><label>18.</label><mixed-citation publication-type="other">Gerhardt, M. J., Priglinger, S. G., Biel, M. &amp; Michalakis, S. Biology, pathobiology and gene therapy of CNG channel-related retinopathies. <italic toggle="yes">Biomedicines</italic><bold>11</bold>10.3390/biomedicines11020269 (2023).<pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/biomedicines11020269</pub-id><pub-id pub-id-type="pmcid">PMC9953513</pub-id><pub-id pub-id-type="pmid">36830806</pub-id></mixed-citation></ref><ref id="CR19"><label>19.</label><citation-alternatives><element-citation id="ec-CR19" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gerhardt</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Petersen-Jones</surname><given-names>SM</given-names></name><name name-style="western"><surname>Michalakis</surname><given-names>S</given-names></name></person-group><article-title>CNG channel-related retinitis pigmentosa</article-title><source>Vis. Res.</source><year>2023</year><volume>208</volume><fpage>108232</fpage><pub-id pub-id-type="pmid">37054604</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.visres.2023.108232</pub-id><pub-id pub-id-type="pmcid">PMC10373105</pub-id></element-citation><mixed-citation id="mc-CR19" publication-type="journal">Gerhardt, M. J., Petersen-Jones, S. M. &amp; Michalakis, S. CNG channel-related retinitis pigmentosa. <italic toggle="yes">Vis. Res.</italic><bold>208</bold>, 108232 (2023).<pub-id pub-id-type="pmid">37054604</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.visres.2023.108232</pub-id><pub-id pub-id-type="pmcid">PMC10373105</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR20"><label>20.</label><citation-alternatives><element-citation id="ec-CR20" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Retinal degeneration in mice lacking the cyclic nucleotide-gated channel subunit CNGA1</article-title><source>FASEB J.</source><year>2021</year><volume>35</volume><fpage>e21859</fpage><pub-id pub-id-type="pmid">34418172</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1096/fj.202101004R</pub-id></element-citation><mixed-citation id="mc-CR20" publication-type="journal">Liu, Y. et al. Retinal degeneration in mice lacking the cyclic nucleotide-gated channel subunit CNGA1. <italic toggle="yes">FASEB J.</italic><bold>35</bold>, e21859 (2021).<pub-id pub-id-type="pmid">34418172</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1096/fj.202101004R</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR21"><label>21.</label><citation-alternatives><element-citation id="ec-CR21" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wu</surname><given-names>Y</given-names></name><etal/></person-group><article-title>AAV-mediated base-editing therapy ameliorates the disease phenotypes in a mouse model of retinitis pigmentosa</article-title><source>Nat. Commun.</source><year>2023</year><volume>14</volume><fpage>4923</fpage><pub-id pub-id-type="pmid">37582961</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41467-023-40655-6</pub-id><pub-id pub-id-type="pmcid">PMC10427680</pub-id></element-citation><mixed-citation id="mc-CR21" publication-type="journal">Wu, Y. et al. AAV-mediated base-editing therapy ameliorates the disease phenotypes in a mouse model of retinitis pigmentosa. <italic toggle="yes">Nat. Commun.</italic><bold>14</bold>, 4923 (2023).<pub-id pub-id-type="pmid">37582961</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41467-023-40655-6</pub-id><pub-id pub-id-type="pmcid">PMC10427680</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR22"><label>22.</label><citation-alternatives><element-citation id="ec-CR22" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Koch</surname><given-names>S</given-names></name><etal/></person-group><article-title>Gene therapy restores vision and delays degeneration in the CNGB1(-/-) mouse model of retinitis pigmentosa</article-title><source>Hum. Mol. Genet.</source><year>2012</year><volume>21</volume><fpage>4486</fpage><lpage>4496</lpage><pub-id pub-id-type="pmid">22802073</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/hmg/dds290</pub-id></element-citation><mixed-citation id="mc-CR22" publication-type="journal">Koch, S. et al. Gene therapy restores vision and delays degeneration in the CNGB1(-/-) mouse model of retinitis pigmentosa. <italic toggle="yes">Hum. Mol. Genet.</italic><bold>21</bold>, 4486&#8211;4496 (2012).<pub-id pub-id-type="pmid">22802073</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/hmg/dds290</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR23"><label>23.</label><citation-alternatives><element-citation id="ec-CR23" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Aizawa</surname><given-names>S</given-names></name><etal/></person-group><article-title>Correlation between visual function and photoreceptor inner/outer segment junction in patients with retinitis pigmentosa</article-title><source>Eye</source><year>2009</year><volume>23</volume><fpage>304</fpage><lpage>308</lpage><pub-id pub-id-type="pmid">18188175</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/sj.eye.6703076</pub-id></element-citation><mixed-citation id="mc-CR23" publication-type="journal">Aizawa, S. et al. Correlation between visual function and photoreceptor inner/outer segment junction in patients with retinitis pigmentosa. <italic toggle="yes">Eye</italic><bold>23</bold>, 304&#8211;308 (2009).<pub-id pub-id-type="pmid">18188175</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/sj.eye.6703076</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR24"><label>24.</label><citation-alternatives><element-citation id="ec-CR24" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tao</surname><given-names>LW</given-names></name><name name-style="western"><surname>Wu</surname><given-names>Z</given-names></name><name name-style="western"><surname>Guymer</surname><given-names>RH</given-names></name><name name-style="western"><surname>Luu</surname><given-names>CD</given-names></name></person-group><article-title>Ellipsoid zone on optical coherence tomography: a review</article-title><source>Clin. Exp. Ophthalmol.</source><year>2016</year><volume>44</volume><fpage>422</fpage><lpage>430</lpage><pub-id pub-id-type="pmid">26590363</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/ceo.12685</pub-id></element-citation><mixed-citation id="mc-CR24" publication-type="journal">Tao, L. W., Wu, Z., Guymer, R. H. &amp; Luu, C. D. Ellipsoid zone on optical coherence tomography: a review. <italic toggle="yes">Clin. Exp. Ophthalmol.</italic><bold>44</bold>, 422&#8211;430 (2016).<pub-id pub-id-type="pmid">26590363</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/ceo.12685</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR25"><label>25.</label><citation-alternatives><element-citation id="ec-CR25" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gong</surname><given-names>Y</given-names></name><name name-style="western"><surname>Chen</surname><given-names>LJ</given-names></name><name name-style="western"><surname>Pang</surname><given-names>CP</given-names></name><name name-style="western"><surname>Chen</surname><given-names>H</given-names></name></person-group><article-title>Ellipsoid zone optical intensity reduction as an early biomarker for retinitis pigmentosa</article-title><source>Acta Ophthalmol.</source><year>2021</year><volume>99</volume><fpage>e215</fpage><lpage>e221</lpage><pub-id pub-id-type="pmid">32701217</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/aos.14542</pub-id></element-citation><mixed-citation id="mc-CR25" publication-type="journal">Gong, Y., Chen, L. J., Pang, C. P. &amp; Chen, H. Ellipsoid zone optical intensity reduction as an early biomarker for retinitis pigmentosa. <italic toggle="yes">Acta Ophthalmol.</italic><bold>99</bold>, e215&#8211;e221 (2021).<pub-id pub-id-type="pmid">32701217</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/aos.14542</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR26"><label>26.</label><citation-alternatives><element-citation id="ec-CR26" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Oh</surname><given-names>JK</given-names></name><name name-style="western"><surname>Nuzbrokh</surname><given-names>Y</given-names></name><name name-style="western"><surname>Lima de Carvalho</surname><given-names>JR</given-names><suffix>Jr.</suffix></name><name name-style="western"><surname>Ryu</surname><given-names>J</given-names></name><name name-style="western"><surname>Tsang</surname><given-names>SH</given-names></name></person-group><article-title>Optical coherence tomography in the evaluation of retinitis pigmentosa</article-title><source>Ophthalm. Genet.</source><year>2020</year><volume>41</volume><fpage>413</fpage><lpage>419</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/13816810.2020.1780619</pub-id><pub-id pub-id-type="pmcid">PMC9362879</pub-id><pub-id pub-id-type="pmid">32552399</pub-id></element-citation><mixed-citation id="mc-CR26" publication-type="journal">Oh, J. K., Nuzbrokh, Y., Lima de Carvalho, J. R. Jr., Ryu, J. &amp; Tsang, S. H. Optical coherence tomography in the evaluation of retinitis pigmentosa. <italic toggle="yes">Ophthalm. Genet.</italic><bold>41</bold>, 413&#8211;419 (2020).<pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/13816810.2020.1780619</pub-id><pub-id pub-id-type="pmcid">PMC9362879</pub-id><pub-id pub-id-type="pmid">32552399</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR27"><label>27.</label><citation-alternatives><element-citation id="ec-CR27" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tanimoto</surname><given-names>N</given-names></name><etal/></person-group><article-title>Vision tests in the mouse: Functional phenotyping with electroretinography</article-title><source>Front Biosci. (Landmark Ed.)</source><year>2009</year><volume>14</volume><fpage>2730</fpage><lpage>2737</lpage><pub-id pub-id-type="pmid">19273231</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2741/3409</pub-id></element-citation><mixed-citation id="mc-CR27" publication-type="journal">Tanimoto, N. et al. Vision tests in the mouse: Functional phenotyping with electroretinography. <italic toggle="yes">Front Biosci. (Landmark Ed.)</italic><bold>14</bold>, 2730&#8211;2737 (2009).<pub-id pub-id-type="pmid">19273231</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2741/3409</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR28"><label>28.</label><mixed-citation publication-type="other">Benchorin, G., Calton, M. A., Beaulieu, M. O. &amp; Vollrath, D. Assessment of murine retinal function by Electroretinography. <italic toggle="yes">Bio Protoc.</italic><bold>7</bold>, 10.21769/BioProtoc.2218 (2017).<pub-id pub-id-type="doi" assigning-authority="pmc">10.21769/BioProtoc.2218</pub-id><pub-id pub-id-type="pmcid">PMC5698848</pub-id><pub-id pub-id-type="pmid">29177186</pub-id></mixed-citation></ref><ref id="CR29"><label>29.</label><citation-alternatives><element-citation id="ec-CR29" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Robson</surname><given-names>AG</given-names></name><etal/></person-group><article-title>ISCEV Standard for full-field clinical electroretinography (2022 update)</article-title><source>Doc. Ophthalmol.</source><year>2022</year><volume>144</volume><fpage>165</fpage><lpage>177</lpage><pub-id pub-id-type="pmid">35511377</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s10633-022-09872-0</pub-id><pub-id pub-id-type="pmcid">PMC9192408</pub-id></element-citation><mixed-citation id="mc-CR29" publication-type="journal">Robson, A. G. et al. ISCEV Standard for full-field clinical electroretinography (2022 update). <italic toggle="yes">Doc. Ophthalmol.</italic><bold>144</bold>, 165&#8211;177 (2022).<pub-id pub-id-type="pmid">35511377</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s10633-022-09872-0</pub-id><pub-id pub-id-type="pmcid">PMC9192408</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR30"><label>30.</label><citation-alternatives><element-citation id="ec-CR30" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jaissle</surname><given-names>GB</given-names></name><etal/></person-group><article-title>Evaluation of the rhodopsin knockout mouse as a model of pure cone function</article-title><source>Invest. Ophthalmol. Vis. Sci.</source><year>2001</year><volume>42</volume><fpage>506</fpage><lpage>513</lpage><pub-id pub-id-type="pmid">11157890</pub-id></element-citation><mixed-citation id="mc-CR30" publication-type="journal">Jaissle, G. B. et al. Evaluation of the rhodopsin knockout mouse as a model of pure cone function. <italic toggle="yes">Invest. Ophthalmol. Vis. Sci.</italic><bold>42</bold>, 506&#8211;513 (2001).<pub-id pub-id-type="pmid">11157890</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR31"><label>31.</label><citation-alternatives><element-citation id="ec-CR31" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Park</surname><given-names>JC</given-names></name><etal/></person-group><article-title>Effects of normal aging on the mouse retina assessed by full-field flash and flicker electroretinography</article-title><source>Sci. Rep.</source><year>2023</year><volume>13</volume><fpage>8860</fpage><pub-id pub-id-type="pmid">37258636</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41598-023-35996-7</pub-id><pub-id pub-id-type="pmcid">PMC10232421</pub-id></element-citation><mixed-citation id="mc-CR31" publication-type="journal">Park, J. C. et al. Effects of normal aging on the mouse retina assessed by full-field flash and flicker electroretinography. <italic toggle="yes">Sci. Rep.</italic><bold>13</bold>, 8860 (2023).<pub-id pub-id-type="pmid">37258636</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41598-023-35996-7</pub-id><pub-id pub-id-type="pmcid">PMC10232421</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR32"><label>32.</label><citation-alternatives><element-citation id="ec-CR32" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yagasaki</surname><given-names>K</given-names></name><name name-style="western"><surname>Miyake</surname><given-names>Y</given-names></name><name name-style="western"><surname>Litao</surname><given-names>RE</given-names></name><name name-style="western"><surname>Ichikawa</surname><given-names>K</given-names></name></person-group><article-title>Two cases of retinal degeneration with an unusual form of electroretinogram</article-title><source>Doc. Ophthalmol.</source><year>1986</year><volume>63</volume><fpage>73</fpage><lpage>82</lpage><pub-id pub-id-type="pmid">3015524</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/BF00153014</pub-id></element-citation><mixed-citation id="mc-CR32" publication-type="journal">Yagasaki, K., Miyake, Y., Litao, R. E. &amp; Ichikawa, K. Two cases of retinal degeneration with an unusual form of electroretinogram. <italic toggle="yes">Doc. Ophthalmol.</italic><bold>63</bold>, 73&#8211;82 (1986).<pub-id pub-id-type="pmid">3015524</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/BF00153014</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR33"><label>33.</label><citation-alternatives><element-citation id="ec-CR33" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Alexander</surname><given-names>KR</given-names></name><name name-style="western"><surname>Fishman</surname><given-names>GA</given-names></name></person-group><article-title>Supernormal scotopic ERG in cone dystrophy</article-title><source>Br. J. Ophthalmol.</source><year>1984</year><volume>68</volume><fpage>69</fpage><lpage>78</lpage><pub-id pub-id-type="pmid">6607068</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/bjo.68.2.69</pub-id><pub-id pub-id-type="pmcid">PMC1040261</pub-id></element-citation><mixed-citation id="mc-CR33" publication-type="journal">Alexander, K. R. &amp; Fishman, G. A. Supernormal scotopic ERG in cone dystrophy. <italic toggle="yes">Br. J. Ophthalmol.</italic><bold>68</bold>, 69&#8211;78 (1984).<pub-id pub-id-type="pmid">6607068</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/bjo.68.2.69</pub-id><pub-id pub-id-type="pmcid">PMC1040261</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR34"><label>34.</label><citation-alternatives><element-citation id="ec-CR34" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Phillips</surname><given-names>MJ</given-names></name><etal/></person-group><article-title>Retinal function and structure in Ant1-deficient mice</article-title><source>Invest. Ophthalmol. Vis. Sci.</source><year>2010</year><volume>51</volume><fpage>6744</fpage><lpage>6752</lpage><pub-id pub-id-type="pmid">20671283</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1167/iovs.10-5421</pub-id><pub-id pub-id-type="pmcid">PMC3055775</pub-id></element-citation><mixed-citation id="mc-CR34" publication-type="journal">Phillips, M. J. et al. Retinal function and structure in Ant1-deficient mice. <italic toggle="yes">Invest. Ophthalmol. Vis. Sci.</italic><bold>51</bold>, 6744&#8211;6752 (2010).<pub-id pub-id-type="pmid">20671283</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1167/iovs.10-5421</pub-id><pub-id pub-id-type="pmcid">PMC3055775</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR35"><label>35.</label><citation-alternatives><element-citation id="ec-CR35" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>H&#252;ttl</surname><given-names>S</given-names></name><etal/></person-group><article-title>Impaired channel targeting and retinal degeneration in mice lacking the cyclic nucleotide-gated channel subunit CNGB1</article-title><source>J. Neurosci.</source><year>2005</year><volume>25</volume><fpage>130</fpage><lpage>138</lpage><pub-id pub-id-type="pmid">15634774</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1523/JNEUROSCI.3764-04.2005</pub-id><pub-id pub-id-type="pmcid">PMC2885903</pub-id></element-citation><mixed-citation id="mc-CR35" publication-type="journal">H&#252;ttl, S. et al. Impaired channel targeting and retinal degeneration in mice lacking the cyclic nucleotide-gated channel subunit CNGB1. <italic toggle="yes">J. Neurosci.</italic><bold>25</bold>, 130&#8211;138 (2005).<pub-id pub-id-type="pmid">15634774</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1523/JNEUROSCI.3764-04.2005</pub-id><pub-id pub-id-type="pmcid">PMC2885903</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR36"><label>36.</label><citation-alternatives><element-citation id="ec-CR36" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pupo</surname><given-names>A</given-names></name><etal/></person-group><article-title>AAV vectors: The Rubik&#8217;s cube of human gene therapy</article-title><source>Mol. Ther.</source><year>2022</year><volume>30</volume><fpage>3515</fpage><lpage>3541</lpage><pub-id pub-id-type="pmid">36203359</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ymthe.2022.09.015</pub-id><pub-id pub-id-type="pmcid">PMC9734031</pub-id></element-citation><mixed-citation id="mc-CR36" publication-type="journal">Pupo, A. et al. AAV vectors: The Rubik&#8217;s cube of human gene therapy. <italic toggle="yes">Mol. Ther.</italic><bold>30</bold>, 3515&#8211;3541 (2022).<pub-id pub-id-type="pmid">36203359</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ymthe.2022.09.015</pub-id><pub-id pub-id-type="pmcid">PMC9734031</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR37"><label>37.</label><mixed-citation publication-type="other">Li, S., Ma, H., Yang, F. &amp; Ding, X. cGMP Signaling in Photoreceptor Degeneration. <italic toggle="yes">Int. J. Mol. Sci</italic>. <bold>24</bold>10.3390/ijms241311200 (2023).<pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/ijms241311200</pub-id><pub-id pub-id-type="pmcid">PMC10342299</pub-id><pub-id pub-id-type="pmid">37446378</pub-id></mixed-citation></ref><ref id="CR38"><label>38.</label><citation-alternatives><element-citation id="ec-CR38" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Petersen-Jones</surname><given-names>SM</given-names></name><etal/></person-group><article-title>Patients and animal models of CNG&#946;1-deficient retinitis pigmentosa support gene augmentation approach</article-title><source>J. Clin. Invest.</source><year>2018</year><volume>128</volume><fpage>190</fpage><lpage>206</lpage><pub-id pub-id-type="pmid">29202463</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1172/JCI95161</pub-id><pub-id pub-id-type="pmcid">PMC5749539</pub-id></element-citation><mixed-citation id="mc-CR38" publication-type="journal">Petersen-Jones, S. M. et al. Patients and animal models of CNG&#946;1-deficient retinitis pigmentosa support gene augmentation approach. <italic toggle="yes">J. Clin. Invest.</italic><bold>128</bold>, 190&#8211;206 (2018).<pub-id pub-id-type="pmid">29202463</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1172/JCI95161</pub-id><pub-id pub-id-type="pmcid">PMC5749539</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR39"><label>39.</label><citation-alternatives><element-citation id="ec-CR39" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wagner</surname><given-names>JE</given-names></name><etal/></person-group><article-title>In vivo potency testing of subretinal rAAV5.hCNGB1 gene therapy in the Cngb1 Knockout Mouse Model of Retinitis Pigmentosa</article-title><source>Hum. Gene Ther.</source><year>2021</year><volume>32</volume><fpage>1158</fpage><lpage>1170</lpage><pub-id pub-id-type="pmid">34376057</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1089/hum.2021.121</pub-id><pub-id pub-id-type="pmcid">PMC8819509</pub-id></element-citation><mixed-citation id="mc-CR39" publication-type="journal">Wagner, J. E. et al. In vivo potency testing of subretinal rAAV5.hCNGB1 gene therapy in the Cngb1 Knockout Mouse Model of Retinitis Pigmentosa. <italic toggle="yes">Hum. Gene Ther.</italic><bold>32</bold>, 1158&#8211;1170 (2021).<pub-id pub-id-type="pmid">34376057</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1089/hum.2021.121</pub-id><pub-id pub-id-type="pmcid">PMC8819509</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR40"><label>40.</label><mixed-citation publication-type="other">Occelli, L. M. et al. Development of a translatable gene augmentation therapy for CNGB1-retinitis pigmentosa. <italic toggle="yes">Mol. Ther</italic>. 10.1016/j.ymthe.2023.04.005 (2023).<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ymthe.2023.04.005</pub-id><pub-id pub-id-type="pmcid">PMC10362398</pub-id><pub-id pub-id-type="pmid">37056049</pub-id></mixed-citation></ref><ref id="CR41"><label>41.</label><citation-alternatives><element-citation id="ec-CR41" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Leconte</surname><given-names>L</given-names></name><name name-style="western"><surname>Barnstable</surname><given-names>CJ</given-names></name></person-group><article-title>Impairment of rod cGMP-gated channel alpha-subunit expression leads to photoreceptor and bipolar cell degeneration</article-title><source>Invest. Ophthalmol. Vis. Sci.</source><year>2000</year><volume>41</volume><fpage>917</fpage><lpage>926</lpage><pub-id pub-id-type="pmid">10711714</pub-id></element-citation><mixed-citation id="mc-CR41" publication-type="journal">Leconte, L. &amp; Barnstable, C. J. Impairment of rod cGMP-gated channel alpha-subunit expression leads to photoreceptor and bipolar cell degeneration. <italic toggle="yes">Invest. Ophthalmol. Vis. Sci.</italic><bold>41</bold>, 917&#8211;926 (2000).<pub-id pub-id-type="pmid">10711714</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR42"><label>42.</label><citation-alternatives><element-citation id="ec-CR42" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wiik</surname><given-names>AC</given-names></name><etal/></person-group><article-title>Progressive retinal atrophy in Shetland sheepdog is associated with a mutation in the CNGA1 gene</article-title><source>Anim. Genet.</source><year>2015</year><volume>46</volume><fpage>515</fpage><lpage>521</lpage><pub-id pub-id-type="pmid">26202106</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/age.12323</pub-id></element-citation><mixed-citation id="mc-CR42" publication-type="journal">Wiik, A. C. et al. Progressive retinal atrophy in Shetland sheepdog is associated with a mutation in the CNGA1 gene. <italic toggle="yes">Anim. Genet.</italic><bold>46</bold>, 515&#8211;521 (2015).<pub-id pub-id-type="pmid">26202106</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/age.12323</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR43"><label>43.</label><citation-alternatives><element-citation id="ec-CR43" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kandaswamy</surname><given-names>S</given-names></name><etal/></person-group><article-title>Mutations within the cGMP-binding domain of CNGA1 causing autosomal recessive retinitis pigmentosa in human and animal model</article-title><source>Cell Death Discov.</source><year>2022</year><volume>8</volume><fpage>387</fpage><pub-id pub-id-type="pmid">36115851</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41420-022-01185-0</pub-id><pub-id pub-id-type="pmcid">PMC9482621</pub-id></element-citation><mixed-citation id="mc-CR43" publication-type="journal">Kandaswamy, S. et al. Mutations within the cGMP-binding domain of CNGA1 causing autosomal recessive retinitis pigmentosa in human and animal model. <italic toggle="yes">Cell Death Discov.</italic><bold>8</bold>, 387 (2022).<pub-id pub-id-type="pmid">36115851</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41420-022-01185-0</pub-id><pub-id pub-id-type="pmcid">PMC9482621</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR44"><label>44.</label><citation-alternatives><element-citation id="ec-CR44" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wu</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Establishment of the induced pluripotent stem cell line SJTUGHi002-A from a CNGA1-related recessive retinitis pigmentosa patient</article-title><source>Stem Cell Res.</source><year>2024</year><volume>76</volume><fpage>103334</fpage><pub-id pub-id-type="pmid">38340451</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.scr.2024.103334</pub-id></element-citation><mixed-citation id="mc-CR44" publication-type="journal">Wu, Y. et al. Establishment of the induced pluripotent stem cell line SJTUGHi002-A from a CNGA1-related recessive retinitis pigmentosa patient. <italic toggle="yes">Stem Cell Res.</italic><bold>76</bold>, 103334 (2024).<pub-id pub-id-type="pmid">38340451</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.scr.2024.103334</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR45"><label>45.</label><mixed-citation publication-type="other">Ayala, A., Cheetham, J., Durham, T. &amp; Maguire, M. The Importance of Natural History Studies in Inherited Retinal Diseases. <italic toggle="yes">Cold Spring Harb. Perspect. Med</italic>. <bold>13</bold>, 10.1101/cshperspect.a041297 (2023).<pub-id pub-id-type="doi" assigning-authority="pmc">10.1101/cshperspect.a041297</pub-id><pub-id pub-id-type="pmcid">PMC9979848</pub-id><pub-id pub-id-type="pmid">36690461</pub-id></mixed-citation></ref><ref id="CR46"><label>46.</label><citation-alternatives><element-citation id="ec-CR46" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Koch</surname><given-names>SF</given-names></name><etal/></person-group><article-title>Halting progressive neurodegeneration in advanced retinitis pigmentosa</article-title><source>J. Clin. Invest.</source><year>2015</year><volume>125</volume><fpage>3704</fpage><lpage>3713</lpage><pub-id pub-id-type="pmid">26301813</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1172/JCI82462</pub-id><pub-id pub-id-type="pmcid">PMC4588299</pub-id></element-citation><mixed-citation id="mc-CR46" publication-type="journal">Koch, S. F. et al. Halting progressive neurodegeneration in advanced retinitis pigmentosa. <italic toggle="yes">J. Clin. Invest.</italic><bold>125</bold>, 3704&#8211;3713 (2015).<pub-id pub-id-type="pmid">26301813</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1172/JCI82462</pub-id><pub-id pub-id-type="pmcid">PMC4588299</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR47"><label>47.</label><citation-alternatives><element-citation id="ec-CR47" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Koch</surname><given-names>SF</given-names></name><etal/></person-group><article-title>Genetic rescue models refute nonautonomous rod cell death in retinitis pigmentosa</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2017</year><volume>114</volume><fpage>5259</fpage><lpage>5264</lpage><pub-id pub-id-type="pmid">28468800</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1073/pnas.1615394114</pub-id><pub-id pub-id-type="pmcid">PMC5441755</pub-id></element-citation><mixed-citation id="mc-CR47" publication-type="journal">Koch, S. F. et al. Genetic rescue models refute nonautonomous rod cell death in retinitis pigmentosa. <italic toggle="yes">Proc. Natl. Acad. Sci. USA</italic><bold>114</bold>, 5259&#8211;5264 (2017).<pub-id pub-id-type="pmid">28468800</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1073/pnas.1615394114</pub-id><pub-id pub-id-type="pmcid">PMC5441755</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR48"><label>48.</label><citation-alternatives><element-citation id="ec-CR48" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kajtna</surname><given-names>J</given-names></name><name name-style="western"><surname>Tsang</surname><given-names>SH</given-names></name><name name-style="western"><surname>Koch</surname><given-names>SF</given-names></name></person-group><article-title>Late-stage rescue of visually guided behavior in the context of a significantly remodeled retinitis pigmentosa mouse model</article-title><source>Cell. Mol. Life Sci.</source><year>2022</year><volume>79</volume><fpage>148</fpage><pub-id pub-id-type="pmid">35195763</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00018-022-04161-0</pub-id><pub-id pub-id-type="pmcid">PMC8866266</pub-id></element-citation><mixed-citation id="mc-CR48" publication-type="journal">Kajtna, J., Tsang, S. H. &amp; Koch, S. F. Late-stage rescue of visually guided behavior in the context of a significantly remodeled retinitis pigmentosa mouse model. <italic toggle="yes">Cell. Mol. Life Sci.</italic><bold>79</bold>, 148 (2022).<pub-id pub-id-type="pmid">35195763</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00018-022-04161-0</pub-id><pub-id pub-id-type="pmcid">PMC8866266</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR49"><label>49.</label><citation-alternatives><element-citation id="ec-CR49" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Scalabrino</surname><given-names>ML</given-names></name><etal/></person-group><article-title>Late gene therapy limits the restoration of retinal function in a mouse model of retinitis pigmentosa</article-title><source>Nat. Commun.</source><year>2023</year><volume>14</volume><fpage>8256</fpage><pub-id pub-id-type="pmid">38086857</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41467-023-44063-8</pub-id><pub-id pub-id-type="pmcid">PMC10716155</pub-id></element-citation><mixed-citation id="mc-CR49" publication-type="journal">Scalabrino, M. L. et al. Late gene therapy limits the restoration of retinal function in a mouse model of retinitis pigmentosa. <italic toggle="yes">Nat. Commun.</italic><bold>14</bold>, 8256 (2023).<pub-id pub-id-type="pmid">38086857</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41467-023-44063-8</pub-id><pub-id pub-id-type="pmcid">PMC10716155</pub-id></mixed-citation></citation-alternatives></ref></ref-list></back></article>
        
    </metadata>
</record>
    </GetRecord>

</OAI-PMH>